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ABSTRACT 
 
Intracellular trafficking of transcription factors is an essential cellular function 
that has implications in regulating gene expression. For thyroid hormone 
receptor (TR), nuclear localization is fundamental to its function of mediating 
gene expression in response to thyroid hormone (T3). Yet, we’ve previously 
shown that TR contains both nuclear localization signals and nuclear export 
signals, and shuttles rapidly between the nucleus and cytosol. Mislocalization 
of TR, and loss of transcriptional control, may lead to negative consequences 
for growth, development, and metabolism. Here, we explore factors that 
enhance nuclear retention of TR. Emerging studies suggest that Mediator 
complex subunit 1 (MED1 or TRAP220), a TR-interacting protein, may 
modulate nuclear retention of TR. To investigate this possibility, 
nucleocytoplasmic distribution and mobility of mCherry-tagged TR subtypes, 
TRα1, TRβ1, and the oncoprotein v-ErbA, were assessed in response to 
MED1 overexpression in HeLa cells. TRα1, which has a predominantly nuclear 
distribution at steady state showed no change in distribution pattern or 
intranuclear mobility when co-transfected with MED1. In contrast, 
overexpression of MED1 caused increased nuclear localization of TRβ1 and v-
ErbA, subtypes with cytosolic populations at steady state, as well as a 
decrease in intranuclear mobility of TRβ1. Interestingly, in the presence of T3, 
which is known to induce phosphorylation of MED1, there was a decrease in 
both nuclear mobility and nuclear retention of TR subtypes. Using TRAP220-/- 
and TRAP220+/+ mouse embryonic fibroblasts (MEF), TR localization in the 
absence of MED1 was subsequently analyzed. Compared to TRAP220+/+ 
cells, TRα1 and TRβ1 showed an increase in cytosolic localization when 
expressed in TRAP220-/- MEFs. Taken together, our data provide evidence for 
MED1 promoting the nuclear retention of TRα1, TRβ1, and v-ErbA. Whether 
increased nuclear retention correlates with increased TR gene transactivation 
requires further analysis. Collectively, our findings implicate MED1 as a 
potential target in the pathogenesis of diseases that are linked to TR 
mislocalization and dysfunction. 
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CHAPTER 1: GENERAL INTRODUCTION 
The nuclear receptor (NR) superfamily is well-characterized for its vital 
role in regulating gene expression. The thyroid hormone receptor (TR), an 
important member of the NR superfamily, was discovered in the early 1970s, 
when its role in binding triiodothyronine (T3) was experimentally determined 
(Oppenheimer et al., 1972). Since its discovery, a tremendous amount of TR-
related research has described its various functions and properties. TR 
functions primarily by binding to thyroid-hormone response elements (TREs) in 
target genes and either activating or repressing TR-regulated genes in response 
to T3. However, it has been shown that TR does not always remain in the 
nucleus and instead can translocate between the nucleus and the cytoplasm 
(Bunn et al., 2001). A significant shift in the balance of TR shuttling towards the 
cytoplasm, therefore, would make it impossible for TR to contact DNA and 
regulate gene expression. This conclusion led to our hypothesis that TR 
mislocalization is a contributing factor to disease pathogenesis (Bonamy et al., 
2005; Bonamy and Allison, 2006), including the TRβ-centric resistance to 
thyroid hormone (RTH) and several types of cancer that result from failed 
regulation in the hypothalamic-pituitary-thyroid (HPT) axis (Brent, 2012; Cheng 
et al., 2010). Recently, the Allison lab has characterized the import and export 
mechanisms controlling TR’s shuttling activity (Grespin et al., 2008; Mavinakere 
et al., 2012; Roggero et al., 2016; Subramanian et al., 2015). Yet, mechanisms 
for controlling TR nuclear retention are yet to be determined. 
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THYROID HORMONE 
Circulation of thyroid hormone is initiated through a complex pathway spanning 
the HPT axis (Fig. 1). The system begins with a hypothalamic protein, 
thyrotropin releasing hormone (TRH), which is transported to and binds with its 
respective receptors in the pituitary gland (Yen, 2001). Here, TRH triggers the 
biogenesis of thyroid stimulating hormone (TSH) (Harris et al., 1978). TSH 
controls regulation of thyroid hormone synthesis through several pathways. In 
brief, they involve the secretion of TSH from the pituitary gland which leads to 
the interaction of TSH with TSH receptors (TSHR) in the thyroid (Yen, 2001). 
Activated TSHR prompts the expression of various proteins involved in 
synthesizing T3 and the more physiologically abundant 3,5,3′,5′-tetraiodo-L-
thyronine, or thyroxine (T4). The concentration of thyroid hormone is regulated 
by thyroid hormone itself, which exerts negative regulation on TSH and TRH 
after a threshold is reached. 
Of the total thyroid hormone produced, T4 is vastly more abundant than 
T3. Yet, T3 is the biologically active form of thyroid hormone that interacts with 
TR. While T4 is known for its longer half-life, its conversion to T3 is catalyzed 
by deiodinases. Most of the T3 circulating the body is bound to various 
molecules. It is estimated that only 0.3% of T3 is unbound and enters cells 
through facilitated transport mechanisms (Yen, 2001). Some of the transporters 
facilitating T3 cell entry include the monocarboxylate transporter 8 (MCT8), 
monocarboxylate transporter 10 (MCT10), and various organic anion-
2
Figure 1. Thyroid hormone production pathway (A) Thyrotropin releasing 
hormone  (TRH) is secreted from the hypothalamus. TRH binds to its receptors 
at the anterior pituitary gland. This leads to activation and release of 
thyroid-stimulating hormone (TSH). TSH binds to its receptors at the thyroid 
gland and thyroid hormone (T3/T4) is released. Thyroid hormone in its active 
form, T3, will interact with target tissue by binding to thyroid hormone receptor 
(TR). After sufficient T3 has been synthesized, it will exert negative feedback to 
prevent overproduction.
3
transporting polypeptides (OATP) (Visser et al., 2011). Once inside the cell, T3 
can interact with TR and induce a cellular response. 
 
THYROID HORMONE RECEPTORS 
Genes and Distribution 
TR is encoded by two separate genes in the human genome: THRA and 
THRB. Chromosome 17 contains THRA while THRB is positioned within 
chromosome 3 (Spurr et al., 1984; Weinberger et al., 1986). Numerous 
subtypes or isoforms of TR exist endogenously and in specific mammalian and 
viral systems. Expression of the THRA gene gives rise to TRα1 and, through 
alternative splicing, two other major isoforms: TRα2 and TRα3. Other isoforms 
also have been discovered by characterizing internal gene promoters (Brent, 
2012; Cheng et al., 2010). Of the TRα isoforms, only TRα1 possesses the T3-
binding site, due to the deletion of the site from the other isoforms during 
alternative splicing (Cheng et al., 2010; Mitsuhashi et al., 1988). Comparable to 
TRα, TRβ has three major isoforms: TRβ1, TRβ2, and TRβ3. The mechanism 
for producing these three separate isoforms for TRβ has been shown to arise 
from expression of the gene at three distinct promoter sites (Williams, 2000; 
Wood et al., 1994). All three isoforms of TRβ are capable of binding T3, 
however, the abundance of TRβ1 is greater and it has a wider distribution in 
mammalian systems than the other isoforms (Brent, 2012). Taking into account 
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the T3-binding ability of TRα1 and the historic scope of the Allison lab, the 
primary focus of this thesis is on TRα1 and TRβ1. 
TRα1 and TRβ1 both exist universally in human tissues, but each is most 
abundant predominantly in specific and differing regions. TRα1 is found mainly 
in brain, heart, and skeletal muscle. TRβ1 is detected in kidneys, liver, brain, 
heart, and thyroid (Cheng et al., 2010). There is significant variability in the 
distribution and abundance of each isoform within different regions of the brain 
itself, as well. Additionally, TRα1 and TRβ1 are shown to be expressed at 
differing concentrations at various points in mammalian development (Bradley 
et al., 1992). 
Protein Domains and Structure 
Both TRα1 and TRβ1 share similarities in protein domain composition: an N-
terminal A/B domain, a DNA-binding domain (DBD), hinge domain, and a 
ligand-binding domain (DBD) (Fig. 2). The LBD, as expected, interacts with 
thyroid hormone. Additionally, the LBD binds with a broad list of coactivators 
and corepressors. These coregulatory interactions can be directly involved in 
transcriptional regulation but also constitute a substantial list of non-
transcriptional roles (Lonard and O’Malley, 2007). Similarly, the A/B domain is 
also commonly involved in transcriptional regulation. The DBD comprises the 
region of TR that interacts with thyroid hormone response elements (TRE). In 
terms of amino acid composition, TRα1 and TRβ1 differ primarily in the A/B 
domain, due to TRβ1 containing a relatively higher number of residues than 
5
Figure 2. Protein structure of TRa1, TRβ1, v-ErbA and MED1 (A) Domain structures of 
TRa1, TRβ1, and v-ErbA (adapted from Mavinakere et al., 2012). The N-terminal A/B domain 
of TRβ1 has more amino acids than that of TRa1. v-ErbA has a viral Gag sequence N-terminal 
to the A/B domain. Besides several mutations in v-ErbA, the domain organization is conserved 
between the three. (B) Regions of MED1 identified for interaction with TR (adapted from 
Fondell, 2013). LxxLL motifs at 604 and 645 identify the point of contact between TRa1 and 
MED1. Thr-1032 and Thr-1457 are phosphorylated by MAPK-ERK when stimulated by EGF 
and/or T3. 
TR
+EGF|T3 +EGF|T3
A
B
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TRα1 (Brent, 2012; Cheng et al., 2010). The A/B domain contains the activation 
function 1 (AF-1) region often implicated in transcriptional regulation (Barettino 
et al., 1994) 
The LBD of both TRα1 and TRβ1 is highly conserved between the isoforms, as 
well as many NRs. A hydrophobic pocket is formed from the chiefly helical 
structure of the LBD, where T3 binds with high affinity to a conserved motif in 
helix 12 (Gronemeyer and Moras, 1998). Within the binding pocket, T4 has an 
acutely lower binding affinity than T3, which is thought to be due to single 
methionine and histidine residues (Wagner et al. 1995). The result leaves the 
TR-T4 interaction as sterically unfavorable. Of the 12 helices comprising the 
LBD, helix 12 has distinguished importance for all NRs due to its roles of 
repositioning the ligand and promoting altered interactions with coregulatory 
proteins (Gronemeyer and Moras, 1998). TR’s helix 12 is contained within the 
highly conserved region of all NR LBD’s designated the activation function 2 
(AF-2) (Gronemeyer and Moras, 1998; Wagner et al. 1995). Akin to the AF-1 
region, AF-2 binds to numerous coregulatory proteins (Barettino et al., 1994), 
including MED1/Trap220, the coactivator protein of interest in this thesis, and is 
therefore a significant component of the LBD moving forward. 
v-ErbA, an oncogenic homolog of TR 
In addition to TRα and TRβ isoforms, v-ErbA, a highly mutated form of TR has 
also been characterized and studied. v-ErbA is encoded by an oncogene carried 
by the avian erythroblastosis virus (AEV) (Beug and Hayman, 1992; Zenke et 
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al., 1990). As described in later sections, the resulting oncoprotein possesses 
several mutations which alter its nucleocytoplasmic transport compared to TR 
subtypes. The protein also has a C-terminal viral Gag sequence clearly not 
present in wildtype TR (Fig. 2). Mechanistically, AEV induces an overexpression 
of both v-ErbA and an oncogenic form of epidermal growth factor receptor 
(EGFR or HER1), v-ErbB (Beug and Hayman, 1992). Together, the 
overproduction of the oncoproteins leads to rapid and commonly fatal 
erythroleukemia in chickens (Beug et al., 1996). v-ErbA contributes to the 
oncogenesis in part by constitutively repressing transcription of genes crucial 
for proper erythrocyte functioning and differentiation (Ciana et al., 1998; Zenke 
et al., 1990). 
v-ErbA also lacks the ability to bind to T3 (Sap et al., 1986). However, its primary 
association with AEV-induced tumorigenesis is amplified by v-ErbA’s dominant-
negative activity against TR. In one study, v-ErbA was shown to bind to TREs 
and effectively block TR from binding (Subauste and Koenig, 1998). As 
discussed below, TR must bind a TRE to regulate T3-responsive genes. 
Blocking the availability of response elements will consequently cause major 
problems in gene regulation. The oncoprotein can also exert dominant negative 
activity by binding to TR and forming a nonfunctional heterodimer that 
neutralizes the interactions required for TR gene regulation (Samuels and 
Selmi, 1991). Similarly, v-ErbA can interact with retinoid X receptor (RXR), a 
protein TR commonly forms heterodimers with, and block TR-RXR dimerization 
(Bonamy et al., 2005; Samuels and Selmi, 1991). 
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There is also evidence for v-ErbA altering TR’s subcellular localization. 
Studies have shown that v-ErbA displays a predominantly cytoplasmic 
subcellular distribution at steady state (Bunn et al., 2001). Along with its 
mechanism for dimerizing with TR, the oncoprotein expands on this by 
sequestering a portion of the wild-type receptor to the cytoplasm and altering 
the export pathway of TR in a concentration-dependent manner (Bonamy et al., 
2005). A closer look showed that cytoplasmic localization leads to the 
development of v-ErbA-induced aggresomes, or distinct puncta resulting from 
accumulation of misfolded proteins. This formation of aggresomes is thought to 
further augment the dominant negative activity of v-ErbA toward TR (Bondzi et 
al., 2011). This type of mislocalization of nuclear proteins to cytoplasmic 
compartments is a key factor in oncogenesis in many different systems. 
Notably, p53, a tumor suppressor, and a mutant form of BRCA1 associated with 
breast cancer development, acquire oncogenic activity following cytoplasmic 
mislocalization and sequestration (Bonamy and Allison, 2006; Rodriguez et al., 
2004; Strommel et al., 1999). Unraveling different strategies against v-ErbA’s 
actions has proven fruitful over the years and a portion of the studies presented 
in this thesis offers additional insight. 
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NUCLEOCYTOPLASMIC SHUTTLING 
Nuclear Pore Complex 
Early efforts in delineating basic structure of the cell nucleus revealed the 
identity of nuclear pore complexes (NPCs) (Callan and Tomlin, 1950). Since 
their discovery, the bidirectional transport of macromolecules between the 
nucleus and cytosol has been studied extensively. NPCs are massive protein 
complexes embedded in nuclear membranes that can range upward of 125 
MDa in size (Reichelt et al., 1990). Architecture of an NPC is composed of a 
family of proteins called nucleoporins. Collectively, the nucleoporins assemble 
into the general NPC structure consisting of a central ring with asymmetric 
arrangement of fibrils extending freely on the cytoplasmic side but arranged into 
a ‘basket’ structure within the nucleoplasm (Hoelz et al. 2011). Proteins smaller 
than ~40 kDa pass through the central channel of the complex by diffusion; 
however, larger proteins require a facilitated transport mechanism discussed 
ahead. Although the exact biophysical forces driving interplay between transport 
proteins and the central nucleoporins are debated, the importance of interacting 
with phenylalanine-glycine repeats (FG repeats) of the nucleoporins to gain 
passage through NPCs is well-accepted (Hoelz et al., 2011; Kabachinski and 
Schwartz, 2015; Suntharalingam and Wente, 2003). To account for larger 
proteins passing through the relatively small diameter of the central ring, the 
functional diameter of NPCs is proposed to respond by dilating extensively 
(Pante and Kann, 2002). 
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Nuclear Localization and Export Sequences 
Localization of proteins to the nucleus is dictated by the presence of 
either one or more nuclear localization signal (NLS) motifs. Classical 
monopartite and bipartite NLS motifs have been widely characterized (McLane 
and Corbett, 2009). For example, the classical monopartite NLS of simian virus 
40 (SV40) contains a stretch of amino acids rich in lysine (K) and arginine (R). 
Furthermore, the classical bipartite NLS, which contains a region of linker amino 
acids flanked by two stretches of basic residues, is exemplified by the 
nucleoplasmin protein in Xenopus laevis (Kalderon et al., 1984; Kalderon et al., 
1984; McLane and Corbett, 2009). Additionally, a class of NLSs (PY-NLS), 
characterized by the standard basic residues bordering proline (P) and tyrosine 
(Y) residues, along with non-classical NLSs have also been well-characterized 
(Süel et al., 2008; Lee et al., 2006; McLane and Corbett, 2009). 
Proteins and RNA in the nucleus that are bound for the cytoplasm instead 
require nuclear export signals (NESs). Motifs for NESs aren’t as well-conserved 
as NLSs; however, a common motif rich in leucine (L) and other hydrophobic 
residues is often present in NRs (Pemberton and Paschal, 2005; Wen et al., 
1995). This leucine-rich hydrophobic motif has been shown to interact with 
CRM1 (chromosomal maintenance 1), also known as XPO1 (exportin 1), in a 
well-characterized CRM1-dependent export pathway (Fukuda et al., 1997; 
Ossareh-Nazari et al., 1997). Additionally, the CRM1-dependent export 
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pathway can be inhibited by a cytotoxic metabolite of Streptomyces, leptomycin 
B (LMB) (Fornerod et al., 1997, Wolff et al., 1997). 
General Transport Mechanism 
The general mechanism for nuclear import of proteins initiates with the 
recognition of an NLS by a specific class of transport receptors, referred to as 
karyopherins. Karyopherins involved with nuclear import, or importins, bind to 
their substrate’s NLS and facilitate entry into the nucleus (Feldherr et al., 1984). 
As previously noted, translocation from the cytoplasm to the nucleus occurs 
through interaction of the importin with the interior FG repeats of the NPC (Hoelz 
et al., 2011). In the nucleoplasm, RanGTP then binds allosterically to the 
importin causing a conformational change and leading to the release of the 
cargo protein within the nucleoplasm (Gorlich et al., 1996). Nuclear export 
instead involves karyopherins termed exportins which interact with NES motifs 
on cargo proteins. Interaction of the exportin-cargo complex with RanGTP is 
required for the complex to exit out through the NPC (Izaurralde et al.,1997). In 
the cytoplasm, the export complex encounters proteins that trigger GTP 
hydrolysis by Ran. The switch to RanGDP induces a conformational change in 
the structure of the exportin causing the cargo to be released freely into the 
cytoplasm (Pemberton and Paschal, 2005). This Ran-mediated process is 
strictly dependent on a gradient created from the high concentration of RanGTP 
in the nucleus relative to the cytoplasm (Izaurralde et al.,1997; Macara, 2001). 
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Proteins containing both an NLS and NES are capable of translocation 
into and out of the nucleus. However, control of localization can be regulated 
through various post-translational modifications and inhibitory macromolecules 
‘masking’ localization sequences to promote or inhibit proteins in the nucleus at 
a given time (McLane and Corbett, 2009). Although TR function is primarily as 
a transcription factor, heterokaryon and FRAP assays have previously shown 
that TR shuttles between the nucleus and the cytoplasm (Bunn et al., 2001; 
Grespin et al., 2008). Therefore, characterization of the various mechanisms 
balancing nuclear import, export, and retention are essential toward 
understanding systems where TR shuttling is proposed to be dysfunctional; i.e., 
RTH and types of cancer. Ultimately, a comprehensive map of these systems 
will assist in developing treatments for thyroid hormone-related diseases. 
TR Nuclear Import 
Nuclear localization signals in TRα1, TRβ1, and v-ErbA have been 
previously addressed. The Hinge domain of TRα1, TRβ1, and v-ErbA contains 
a well conserved classical bipartite NLS (Mavinakere et al., 2012). However, 
prior investigations pointed toward the presence of an additional NLS in TRα1 
based on observations that TRβ1 exhibited a greater cytoplasmic distribution 
relative to TRα1 (Baumann et al., 2001; Zhu et al., 1998). NLS-2, a monopartite 
NLS, was subsequently identified in the A/B domain of TRα1; notably, this NLS 
is not present in TRβ1 (Mavinakere et al., 2012). Interestingly, a naturally 
occurring single amino acid substitution in the conserved region of NLS-2 
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present in v-ErbA completely ablates the function of the NLS (Mavinakere et al., 
2012). Therefore, only TRα1 contains an active monopartite NLS-2. 
In addition to the localization sequences that have been identified, the 
importins involved in facilitating nuclear import have been identified. The 
classical model for nuclear import involves the formation of a heterodimeric 
complex between adaptor importin α and importin β1, where importin α binds 
the cargo protein NLS and importin β1 interacts with the FG repeats of the NPC 
(Görlich et al., 1995; Lange et al., 2007). Recently, it has been shown that NLS-
1 in the Hinge region of TRα1 and TRβ1 interacts with the importin α1/β1 
complex (Roggero et al., 2016) (Fig. 3). Along with the importin α1/β1 pathway, 
importin 7 was also found to interact with NLS-2 of TRα1. However, since TRβ1 
and v-ErbA both lack NLS-2, these proteins only utilize the importin α1/β1 import 
pathway (Roggero et al., 2016). Aside from the interactions between the 
importins and their respective NLSs, it has been shown that the A/B domain, 
DBD, and hinge domain are all required for complete nuclear localization of 
TRα1 (Mavinakere et al., 2012). 
TR Nuclear Export 
TRα1 and TRβ1 have been shown to contain a completely conserved NES in 
helix 12 of the LBD (NES-H12); however, v-ErbA lacks this sequence in the 
same position (Mavinakere et al., 2012). Two separate monopartite NESs have 
been identified in helix 3 (NES-H3) and helix 6 (NES-H6) of the TRα1 LBD and, 
based on sequence homology, are predicted to be within TRβ1 and v-ErbA, as 
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well (Mavinakere et al., 2012). v-ErbA uniquely possesses a leucine-rich NES 
present in the viral Gag sequence fused to the N-terminal end of the protein 
(DeLong et al., 2004). 
TR was previously reported to only follow CRM1-independent export pathways, 
similar to many steroid receptors, due to the insensitivity of TR export to LMB 
(Black et al., 2001; Bunn et al., 2001). However, recently it has been shown that 
export of TR is facilitated through both CRM1-dependent and independent 
pathways. In the CRM1-dependent pathway, TRα1 interacts with a complex of 
CRM1 and calreticulin (CRT) which facilitates rapid export (Grespin et al., 
2008). Additionally, the nuclear export of v-ErbA is completely controlled by the 
same CRM1-dependent pathway involving its leucine-rich NES (DeLong et al., 
2004). However, when treated with LMB, TRα1 was still capable of export to the 
cytoplasm, solidifying the need to characterize a CRM1-independent export 
pathway (Grespin et al., 2008). Recently, exportins 4, 5, and 7 have collectively 
been found to be involved with this expected CRM1-independent export 
pathway (see Fig. 3). Similarly, TRβ1 export is facilitated by exportins 5 and 7 
(Subramanian et al., 2015). The exact binding interactions between exportins 
and corresponding NESs on TRα1 and TRβ1 is still yet to be characterized. 
 
NUCLEAR RETENTION 
Proteins native to the nucleus often rely on several regulatory mechanisms to 
control not only functionality, but also nuclear localization. A central focus of this 
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thesis is to unravel fundamental ways in which TR, specifically, is retained in 
the nucleus rather than being exported. However, pursuing compartment-
specific localization first requires an understanding of the biophysical dynamics 
of intranuclear protein movement. 
Protein movement is commonly depicted as nonrandom motion facilitated by 
cytoskeletal motors (Brangwynne et al., 2008). While relevant, this thesis 
research instead focuses on protein migration described by Brownian motion. 
Early studies of Brownian motion explained how directional movement of foreign 
molecules in a solvent is affected by random collisions with the molecules 
constituting the solvent itself (Einstein, 1905). Application of these kinetics led 
to an understanding of how nuclear proteins adopt diffusional movement 
through the nucleoplasm (Phair and Misteli, 2000). Contrary to predictions 
based on Einstein’s equation for diffusion, it has been shown that viscosity does 
not significantly affect the diffusion in different compartments (Einstein, 1905; 
Lukacs et al., 200). Instead, characterizing movement of proteins like NRs 
requires greater emphasis on the concentration of the proteins in bound versus 
unbound states. Therefore, freely diffusing NRs are identified as being in a 
“mobile” state. On the other hand, NRs actively involved in gene regulation will 
be interacting with DNA in an “immobile” state. Although bound versus unbound 
is frequently decided by protein-protein interactions, Phair and Misteli (2000) 
described how affinity for distinct sub-compartments of the nucleus can also 
further affect the estimated mobility of proteins. Collectively, persuasive 
strategies for assessing changes in nuclear retention of proteins requires 
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incorporation of assays aimed at both identifying compartmental localization of 
a protein and measuring intranuclear mobility. 
A common method for studying intranuclear mobility is fluorescence recovery 
after photobleaching (FRAP) using confocal microscopy. FRAP takes 
advantage of proteins that are fluorescently labeled, such as nuclear proteins 
tagged with green fluorescent protein (GFP). The resulting excitation and 
emission of GFP can be ablated by extensive photobleaching. To achieve this 
irreversible photobleaching, confocal lasers are often set to maximal power 
briefly during imaging (time ≤ 1s) across a small section of the nucleus. As 
proteins diffuse through the nucleoplasm post-bleach, the unbleached 
fluorescent-proteins will eventually mix into the bleached region over time, 
yielding a recovery curve. The resulting recovery curve can then reveal dynamic 
properties of the nuclear protein such as recovery rate, mobile fraction, 
immobile fraction, half-time, and an estimated rate of diffusion through the 
nucleus (Carrero et al., 2003). Each of these factors are affected by the balance 
between mobile and immobile states of proteins. 
As previously mentioned, the mobility of NRs can be affected by 
localizing to different compartments within the nucleus (Phair and Misteli, 2000). 
Beyond this, the mobility of TR is affected by other factors including protein-
protein interactions, ligand-binding, and DNA binding (Rentoumis et al., 1990, 
Yen, 2001). TR FRAP studies have previously shown that the mobility of TR is 
relatively unaffected by the presence or absence of T3 (Maruvada et al., 2003). 
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However, it is possible that TR’s interaction with coregulators may have a 
greater effect on TR’s nuclear retention. Baumann et al. (2000) demonstrated 
how the presence of nuclear receptor corepressor (NCoR) increases TR’s 
nuclear retention by decreasing nucleocytoplasmic shuttling; however, 
mutations that were introduced to disrupt protein-protein interactions would 
have disrupted NESs as well, so these studies remain inconclusive. Therefore, 
the potential of other coregulators to influence TR’s retention requires further 
analysis. 
 
TR TRANSCRIPTIONAL REGULATION 
The main functional implications of TR nucleocytoplasmic shuttling are centered 
around its ability to regulate the expression of genes in response to thyroid 
hormone. Many NRs are sequestered to the cytosol in the absence of ligand 
and upon ligand interaction will translocate to the nucleus where they interact 
with DNA response elements (Yamamote, 1985). For example, in the absence 
of ligand, the glucocorticoid receptor (GR) is present in the cytoplasm bound to 
a heat shock protein 90 (hsp90) chaperone complex. Then, ligand-binding 
triggers a conformational change which allows for interaction of the nuclear 
import machinery with GR’s NLS to then translocate the complex into the 
nucleus (Vandevyver et al., 2012). In contrast to other NRs, TR can 
constitutively bind to a TRE both in the presence and absence of its ligand, T3 
(Rentoumis et al., 1990). During its interaction with TREs, TR can bind as a 
18
monomer, homodimer, or heterodimer with other NRs. The retinoid X receptor 
(RXR) is commonly found to dimerize with TR (Xiao-kun et al., 1992). In the 
absence of ligand, TR dimers associate with a wide range of transcriptional 
corepressors. On the contrary, if T3 is present, TR undergoes conformational 
changes which release corepressor proteins and instead recruit coactivators. 
Part of this control can be attributed to the many negative and positive TREs 
discovered upstream and in untranslated regions of T3-regulated genes (Carr 
and Wong, 1994; Kim et al., 1992). In conjunction with the differing activity of 
response elements, a wide range of proteins have been characterized as 
coregulators that complement the regulatory functions of TR. 
A commonly cited corepressor associated with TR is NCoR1 and its 
variants (Brent, 2012; Yen, 2001). NCoR1 has been shown to assist TR in 
repressing transcription of target genes (Hörlein et al, 1995). A similar protein, 
NCoR2 (also known as SMRT), was shown to have a nearly identical role as 
NCoR1. Together TR’s interactions with NCoR1 and NCoR2 show that not only 
is the LBD important for coregulatory interaction but the Hinge domain, as well 
(Yen, 2001). TR and NCoR1 have also been implicated in interacting with 
various basal transcription factors (Baniahmad et al., 1993; Hörlein et al, 1995; 
Yen, 2001). Furthermore, TR and its NCoR1-silencing complex have been 
shown to interfere with the assembly of the transcriptional pre-initiation complex 
(PIC) as a mechanism for gene suppression in the absence of T3 (Fondell et 
al., 1993). TR’s negative regulation of genes also extends to chromatin 
remodeling. Its association with various histone deacetylases (HDACs), such 
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as HDAC1, solidifies an epigenetic mechanism to introduce chromatin 
compaction and further inhibit assembly of the PIC (Alland et al., 1997). While 
corepressors are of interest to the Allison lab, this thesis focuses on TR’s 
interaction with a coactivator. 
Not surprisingly, there is also an exceedingly broad list of coactivators 
found to interact with TR. Steroid receptor co-activator 1 (SRC-1) has gained 
unique notoriety with TR due to its role in provoking RTH characteristics when 
its binding site in TR is mutated (Weiss et al., 1999). Another coactivator, 
TRIP230, has been shown to drastically upregulate the expression of TR-
dependent genes (Chang et al., 1997). 
Specifically, this thesis research focuses on factors that promote TR’s 
nuclear retention. The problem with studying coactivators such as SRC-1 and 
TRIP230 is that they localize to many different organelles within the cell 
(Anbalagan et al., 2012; Chen et al., 1999). To find more promising candidates 
for promoting nuclear retention, we instead focused on TR-associated 
coactivators, in particular those identified as the thyroid-hormone associated 
proteins (TRAPs) (Fondell et al., 1996). This family of activators now is known 
to include many of the subunits that make up the transcriptional Mediator 
complex (Fondell et al., 1996; Ito and Roeder, 2001). 
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MEDIATOR COMPLEX AND PRE-INITIATION COMPLEX 
The transcriptional pre-initiation complex (PIC) includes a diverse range 
of proteins complexed together to facilitate transcription. Incorporated into this 
massive structure is RNA Polymerase II (Pol II), basal transcription factors, 
coregulatory proteins, and chromatin remodeling complexes (see Fig. 3). 
Among these general PIC components is the Mediator complex, a 1.2 MDa 
composite of 26-30 subunits that was originally isolated from yeast (Thompson 
et al., 1993). The various Mediator subunits are isolated into four distinct regions 
of the complex. These structural regions are referred to as the head, middle, 
tail, and cyclin-dependent kinase (CDK) region (Wang and Yin, 2014). However, 
complexes isolated from various cell types have shown that several subunits of 
Mediator are variably absent from fully functional complexes (Allen and Taatjes, 
2015). Although this may cause some dysfunction, it rarely disrupts the integrity 
of Mediator assembling the PIC (Allen and Taatjes, 2015). The CDK region 
provides an example of subunit variability, as this region has its own control 
mechanism for associating with and dissociating from Mediator that can dictate 
Mediator’s interaction with Pol II (Knuesel et al., 2009). The control of the CDK 
region is situation-specific, such that CDK8 may be bound and function 
appropriately, but simultaneous binding of CDK19 with CDK8 is a proposed 
mechanism for disease onset (Allen and Taatjes, 2015). 
Mediator is most notable for being involved in recruiting various members 
of the PIC to eukaryotic gene promoters (Baek et al., 2006). This includes direct 
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interaction with TFIIB and Pol II (Baek et al., 2006). However, Mediator has 
been implicated in all phases of transcription, from chromatin remodeling to 
splicing of the primary transcript. Additionally, Mediator is involved in in post-
translational processing and has distinct enzymatic properties in various 
subcellular compartments (Poss et al., 2013). By association, the individual 
subunits are known to be incredibly versatile in function within the scope of 
these transcription-related processes (Yin and Wang, 2014). The bottom line is 
that Mediator plays a critical role in cellular and organismal development. 
 
MEDIATOR COMPLEX SUBUNIT 1—TRAP220/MED1 
MED1, also known as TRAP220, PBP, and DRIP205, is a 220 kDa, 1,581 
residue protein subunit of Mediator. To make Mediator subunits more 
comparable between researchers, a naming system was initially agreed upon, 
deeming this subunit officially TRAP220 in human systems (Bourbon et al., 
2004). However, a more recent adaptation of this system lists the Mediator 
subunits as “MEDs” (Robinson et al., 2015). For this thesis, depending on 
context, MED1 and TRAP220 will be used interchangeably. 
MED1 is structurally found within the middle and tail region of Mediator. 
Here, it most notably interacts with MED26, which together, form an internal 
bridge between the middle and tail clusters (Poss et al., 2013). The variable 
recruitment of MED1 and MED26 are unique to other Mediator subunits in that 
they are commonly found to both be absent from the same endogenous 
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Mediator complexes (Zhang et al., 2005; Taatjes and Tjian, 2004). Studies using 
MED1/TRAP220-/- mice have demonstrated the importance of MED1 during 
embryonic development (Ito et al., 2000). TRAP220-/- mouse embryos had failed 
organ development and eventually died (Ito et al., 2000; Landles et al., 2003). 
Therefore, although Mediator can function in the absence of MED1 in adult 
tissues, MED1 is clearly essential for proper development. 
MED1 protein domains are still poorly defined; however, some distinct regions 
are currently well-characterized for interacting with NRs (see Fig. 2) (Fondell, 
2013). The most relevant here are two regions termed nuclear-receptor boxes 
(NR boxes) or the preferred receptor-binding domains 1 and 2 (RBD-1 and 
RBD-2) which serve as sites for MED1-NR interactions. RBD-1 and RBD-2 both 
contain the conserved leucine-rich, LxxLL motifs, commonly found in 
coregulatory proteins that interact with NRs via the AF-2 region of the LBD 
(Gronemeyer and Moras, 1998; Ren et al., 2000). This interaction therefore has 
MED1 bridging the interaction between various NRs to the Mediator complex 
(see Fig. 3). The list of NRs interacting with MED1 includes TR, GR, vitamin D 
receptor (VDR), peroxisome proliferator-activated receptor (PPAR), estrogen 
receptor, and androgen receptor (Chen and Roeder, 2007; Kang et al., 2002; 
Ren et al., 2000; Wang et al., 2002). Furthermore, Ren et al. (2000), found that 
TR, VDR, and PPAR, all bind with higher affinity specifically to MED1’s RBD-2, 
rather than to RBD-1, due to a greater number of basic residues flanking RBD-
2 which promote electrostatic interactions. 
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Aside from the RBDs, two threonines at residues 1032 and 1457 serve 
as targeted sites of phosphorylation for mitogen-activated protein kinase 
extracellular signal-regulated kinase (MAPK-ERK) (Pandey et al., 2005). More 
recent reports show that MED1 is also phosphorylated at serine-672 by CHK2 
kinase, a mechanism implicated in DNA damage (Kim et al., 2017). 
Phosphorylation of MED1 leads to critical changes in protein activity. One study 
showed the phosphorylated MED1 has a significantly increased half-life in cells 
compared to the dephosphorylated form (Pandey et al., 2005). Phosphorylated 
MED1 also has an increased and augmented association with the Mediator 
complex due to greater interaction with the MED7 subunit (Belakavadi et al., 
2008). Based on MED1’s variable association with Mediator endogenously, 
phosphorylation has been hypothesized as a crucial post-translational 
modification regulating the interaction MED1 has with NRs, including TR 
(Belakavadi et al., 2008; Fondell, 2013; Pandey et al., 2005). 
 
TR-MED1 INTERACTION 
Previously, the Mediator complex has been probed for interacting with TR 
subtypes. Interaction of Mediator with TRα1 has been pursued far more than 
interaction with TRβ1; however, Zhu et al. (1997) showed that a synthetically 
truncated form of MED1 interacts with TRβ1. Studies on TRα1 and Mediator 
show direct interaction between MED1 and TRα1 (Fondell et al., 1996). As for 
other NRs, the proteins interact by contact between the LxxLL motifs in RBDs 
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of MED1 and residues in the C-terminal portion of TR’s LBD (Ren et al., 2000; 
Yuan et al. 1998). Binding of MED1 with TRα1 also occurs in a ligand-
dependent manner, observed by comparing liganded to unliganded TRα1, 
which shows no association with MED1 (Fondell et al., 1996). As previously 
discussed, binding of TR to its ligand, T3, is required to initiate TR’s role as a 
transcriptional activator on positive TREs. Therefore, these previous findings 
reveal MED1’s role as a coregulator of TR-associated genes. 
Research groups have further investigated the MED1-TR interaction and 
the extent to which it affects TR-dependent gene expression. Studies using 
TRAP220-/- mouse embryonic fibroblasts (MEFs) demonstrated this point by 
showing that activation of TR-associated genes was inhibited in the TRAP220-
/- cell, and that transcriptional output could be rescued by expression of 
exogenous MED1 in the fibroblasts (Ito et al., 2000; Malik et al., 2004). MED1 
co-regulation of TR-associated gene expression can also be enhanced by ERK 
phosphorylation of MED1 (see Fig. 2). Furthermore, MAPK-ERK has been 
shown to be activated by T3, with levels proportionate to a known ERK activator, 
epidermal growth factor (EGF) (Pandey et al., 2005). Thus, not only does the 
presence of T3 and MED1’s phosphorylation by MAPK-ERK regulate the TR-
MED1 interaction, but it can also dictate the degree of TR-regulated gene 
transactivation (Pandey et al., 2005; Belakavadi et al., 2008). While MED1-
TRα1 binding has been explored for its effect on gene expression, its effect on 
TR intracellular localization has not been investigated. 
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Figure 3. TR nuclear import, export, and interaction with MED1. Importin (IPO) a1, β1, and/or 7 facilitating 
import of TR through the NPC into the nucleus. In the nucleus, TR is bound to TRE while simultaneously 
interacting with MED1. MED1 is complexed within Mediator which is functioning as a component of the PIC. To 
shuttle back into the cytoplasm, TR binds with exportin (XPO) 4, 5, and/or 7 and the translocates back out 
through an NPC.
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THESIS OBJECTIVE 
Retention of TR within the nucleus is essential for TR-associated gene silencing 
or transactivation. Characterization of TR shuttling between the nucleus and the 
cytosol, along with identification of multiple import and export signals, has 
highlighted the need to elucidate how the balance between nuclear import, 
export, and retention is maintained. Further insight into the relationship between 
these mechanisms will provide a better understanding of how TR mislocalization 
may lead to disease (Bonamy et al., 2005; Bonamy and Allison, 2006; 
Mavinakere et al., 2012). TR’s nuclear import and export systems have 
garnered considerable attention recently, which has revealed many 
components. The Allison lab has previously shown that T3 is one factor that 
promotes the nuclear retention of TR (Bonamy and Allison, 2006; Bunn et al., 
2001); however, additional mechanisms for nuclear retention of TR are poorly 
defined. 
The overall objective of this thesis research was to expand understanding of 
factors that play a role in TR nuclear retention. As discussed, great attention 
has been given to MED1’s role as a coactivator for TR-regulated gene 
transcription. Therefore, MED1 provides a promising candidate for influencing 
TR’s retention in the nucleus (see Fig. 3). This thesis research specifically 
focused on the effect of MED1 on TR’s nucleocytoplasmic distribution and 
intranuclear mobility. These two characteristics were assessed when MED1 
was overexpressed, knocked-out, or phosphorylated. Additionally, previous 
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studies on MED1 and TR have primarily dealt with TRα1, and some aspects of 
this earlier work also used synthetically truncated forms of MED1, particularly 
for analysis of phosphorylated MED1. Therefore, part of this thesis was also 
devoted to examining MED1’s relationship with TRβ1 and the oncoprotein v-
ErbA. 
The following three specific aims were investigated in this thesis 
research: 
1. Evaluate if overexpression of MED alters the nuclear retention of TR 
2. Assess the impact that knockout of MED1 has on nuclear retention of 
TR 
3. Elucidate how nuclear retention of TR is affected by MED1 
phosphorylation by ERK. 
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ABSTRACT 
Intracellular trafficking of transcription factors is an essential cellular function 
that has implications in regulating gene expression. For thyroid hormone 
receptor (TR), nuclear localization is fundamental to its function of mediating 
gene expression in response to thyroid hormone (T3). Yet, we’ve previously 
shown that TR contains both nuclear localization signals and nuclear export 
signals, and shuttles rapidly between the nucleus and cytosol. Mislocalization 
of TR, and loss of transcriptional control, may lead to negative consequences 
for growth, development, and metabolism. Here, we explore factors that 
enhance nuclear retention of TR. Emerging studies suggest the likelihood that 
Mediator complex subunit 1 (MED1 or TRAP220), a TR-interacting protein, 
modulates nuclear retention of TR. To investigate this possibility, 
nucleocytoplasmic distribution and mobility of mCherry-tagged TR subtypes, 
TRα1, TRβ1, and the oncoprotein v-ErbA, was assessed in response to MED1 
overexpression in HeLa cells. TRα1, which has a predominantly nuclear 
distribution at steady state showed no change in distribution pattern or 
intranuclear mobility when co-transfected with MED1. In contrast, 
overexpression of MED1 caused increased nuclear localization of TRβ1 and v-
ErbA, subtypes with cytosolic populations at steady state, as well as a decrease 
in intranuclear mobility of TRβ1. Interestingly, in the presence of T3, which is 
known to induce phosphorylation of MED1, there was a decrease in both 
nuclear mobility and nuclear retention of TR subtypes. Using TRAP220-/- and 
TRAP220+/+ mouse embryonic fibroblasts (MEFs), TR localization in the 
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absence of MED1 was subsequently analyzed. Compared to TRAP220+/+ cells, 
TRα1 and TRβ1 showed an increase in cytosolic localization when expressed 
in TRAP220-/- MEFs. Taken together, our data provide evidence for MED1 
promoting the nuclear retention of TRα1, TRβ1, and v-ErbA. Whether increased 
nuclear retention correlates with increased TR gene transactivation requires 
further analysis. Collectively, our findings implicate MED1 as a potential target 
in the pathogenesis of diseases that are linked to TR mislocalization and 
dysfunction. 
 
INTRODUCTION 
Thyroid hormone receptor (TR), a member of the (NR) superfamily, is 
expressed as two major subtypes, TRα1 and TRβ1. TR functions primarily as a 
transcription factor capable of both activating and inhibiting the expression of 
various genes in response to thyroid hormone (T3). In contrast to many nuclear 
receptors that require interaction with ligand before translocating to the nucleus 
and interacting with DNA, TR is constitutively bound to its respective thyroid 
hormone response element (TRE), in the absence of ligand (Brent, 2012). 
Constitutive interaction with DNA implies that TR would have a predominantly 
nuclear localization. However, we previously demonstrated that TR exhibits 
shuttling activity between the nucleus and cytoplasm (Bunn et al., 2001). 
Mislocalization of TR to the cytoplasm has the potential to disrupt its role 
regulating gene expression. Studies using v-ErbA, an oncogenic homolog of TR 
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that localizes mainly to the cytoplasm, point to mislocalization as a possible 
mechanism for oncogenesis (Bonamy et al., 2005: Bonamy and Allison, 2006; 
Bondzi et al., 2011). Resistance to Thyroid Hormone (RTH), a disease which 
causes symptoms of both hypo- and hyperthyroidism, is also linked to several 
TR mutations, primarily with TRβ (Yen et al., 2001), and mislocalization may 
contribute to its development (Mavinakere et al., 2012). More recently, several 
different mutations have been found in TRα1 that lead to RTH (Schoenmakers 
et al., 2013). Therefore, unraveling how the balance of TR’s nuclear import, 
retention, and export is controlled will provide further insight into TR-associated 
disease pathogenesis. 
Recently, our understanding of TR’s nuclear import and export pathways has 
expanded considerably. In addition to a well-conserved nuclear localization 
signal (NLS) in the Hinge domain of TRα1 and TRβ1, termed NLS-1, TRα1 has 
an additional NLS, NLS-2, in its A/B transactivation domain which enhances its 
localization to the nucleus relative to TRβ1 (Mavinakere et al., 2012). NLS-1 
facilitates nuclear import through interaction with the importin α1/β1 karyopherin 
complex, while NLS-2 is associated with the importin 7 pathway (Roggero et al., 
2016). In addition to import signals, multiple nuclear export signals (NESs) have 
been characterized, as well. Two distinct monopartite NESs were characterized 
within helix 3 and helix 6 of TRα1 and predicted to also be within TRβ1 and v-
ErbA (Mavinakere et al., 2012). However, an additional NES is also found within 
helix 12 (NES-H12) of TRα1 and TRβ1’s ligand binding domain (LBD), which is 
absent in v-ErbA (Mavinakere et al., 2012). Instead, v-ErbA has a unique NES 
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in its C-terminal viral Gag sequence (DeLong et al., 2004). Nuclear export 
occurs through both CRM1-dependent and CRM1-independent pathways. 
Different from TRα1 and TRβ1, v-ErbA is strongly exported by a CRM1-
dependent pathway, resulting in greater cytoplasmic distribution relative to 
TRα1 and TRβ1 (Bunn et al., 2001; DeLong et al., 2004). CRM1-dependent TR 
export involves interaction with calreticulin and can be partially inhibited by 
Leptomycin B, a cytotoxin produced by Streptomyces (Fornerod et al., 1997, 
Grespin et al., 2008; Wolff et al., 1997). On the other hand, CRM1-independent 
export of TR involves several other exportins. Our investigation of this 
mechanism revealed that TR interacts with exportins 4, 5, and 7 (Subramanian 
et al., 2015). While recent discoveries have enhanced our understanding of 
nuclear import and export, characterization of factors promoting TR’s retention 
to the nucleus remain unclear. 
TR has been found to interact with various subunits of the Mediator complex. 
Specifically, TRα1 and TRβ1 directly bind with Mediator complex subunit 1 
(MED1), also called TRAP220 (Fondell et al., 1996; Zhu et al., 1997). Receptor 
binding domains present in MED1 contain leucine-rich LxxLL motifs which 
interact with the activation function 2 (AF2) region of TR’s LBD (Ren et al., 2000; 
Yuan et al. 1998). Phosphorylation of MED1 by MAPK-ERK at two threonine 
residues further promotes this interaction and can be stimulated by both 
epidermal growth factor (EGF) and T3 (Pandey et al., 2005). This 
phosphorylated state also activates TR’s role as a coactivator for TR-regulated 
gene expression (Belakavadi et al., 2008). Conversely, TR’s gene 
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transactivation activity has been shown to be ablated in MED1/TRAP220-/- 
mouse embryonic fibroblasts (MEFs), but can be reversed by adding MED1 
back into the cells (Ito et al., 2000; Malik et al., 2004). Collectively, studies have 
established the significance of binding MED1 for proper TR-associated 
transcriptional regulation. 
Here, we investigated how the presence or absence of MED1 affects nuclear 
retention of TRα1, TRβ1, and v-ErbA in transfected HeLa cells by using 
fluorescence recovery after photobleaching (FRAP) mobility assays and 
fluorescence-assisted nucleocytoplasmic scoring. Our data suggest that MED1 
indeed plays a significant role in the nuclear retention of TRα1 and TRβ1. MED1 
also promotes retention of v-ErbA; however, coimmunoprecipitation 
experiments need to be implemented to determine whether this is from directly 
binding with MED1 or by an alternative indirect mechanism. We also sought to 
assess the impact of MED1 phosphorylation by MAPK-ERK on TR’s 
localization. We found that T3-stimulated phosphorylation of MED1 led to 
increased mobility of TRβ1 and decreased nuclear retention. Additionally, EGF-
stimulated MED1 phosphorylation caused a reduction in the mobile fraction of 
TRα1. Collectively, our assays suggest that MED1 is a key factor in decreasing 
the intranuclear mobility of TR and thereby promoting its nuclear retention. 
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EXPERIMENTAL PROCEDURES 
Plasmids – Plasmids were bacterially cultured and purified from competent E. 
coli. EGFP-C1 and pmCherry-C1 were obtained from Clontech Laboratories, 
Inc. Preparation of the mCherry-TRα1 and mCherry-v-ErbA expression vectors 
were performed by subcloning the corresponding coding regions from 
previously prepared GFP-TRα1 and GFP-v-ErbA (Bunn et al., 2001) into the 
pmCherry-C1 (Clontech) vector. mCherry-TRβ1 was similarly prepared (by V. 
Roggero) through subcloning the TRβ1 coding sequence from GFP-TRβ1 
(Subramanian et al., 2015), encoding functional GFP-tagged human TRβ1, into 
the pmCherry-C1 vector. GFP-GST-GFP(G3)-Hinge, containing the TR NLS-1, 
expression plasmid was previously described (Mavinakere et al., 2012). 
GFPSpark-MED1 was obtained from Sino Biological Inc. and encodes human 
MED1, truncated from residues 547-1581. The expression plasmid for GFP-
tagged full length human MED1 (residues 1-1581) was acquired from OriGene 
Technologies, Inc. pEGFP-GR expression plasmid was from Addgene (plasmid 
#47504; Alice Wong). 
Mouse Embryonic Fibroblasts (MEFs) – Assays investigating the effects of 
MED1 knockout were conducted using Trap220+/+ and Trap220-/- MEFs. The 
MEFs were a gift from the lab of Dr. Robert Roeder (Rockefeller University). 
Further details regarding both the preparation of the MEFs and generation of 
Trap220+/+ and Trap220-/- mice can be found in Ito et al. (2000). 
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Cell Culture and Transfection - HeLa cells were cultured in Minimum Essential 
Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco), or 10% 
FBS-MEM, at 37˚C, 5% CO2, and 98% humidity to 70 – 90% confluency. MEFs 
were cultured in Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 
10% Newborn Calf Serum (Gibco), or 10% NCS-DMEM. Cells were displaced 
with 0.25% trypsin (Gibco). 6-well culture dishes were seeded at a density of 
2.5 x 105 per well on coverslips and incubated for ~24 h. Plates were then 
transfected or cotransfected with 1 μg of either mCherry-TRα1, mCherry-TRβ1, 
or mCherry-v-ErbA and 1 μg of either truncated or full-length GFP-MED1 
expression plasmids. Lipofection for HeLa cells was facilitated by Lipofectamine 
2000 (Invitrogen) in Opti-MEM 1 Reduced Serum Medium (Invitrogen). 
Lipofectamine 3000 (Invitrogen) in Opti-MEM 1 Reduced Serum Medium 
(Invitrogen) was used for transfecting MEFs. Both Lipofectamine 2000 and 3000 
were used according to the manufacturer’s protocol. 
Quantitative Analysis of Nucleocytoplasmic Distribution – Eight hours post-
transfection, transfection mixtures were replaced with the respective 10% FBS-
MEM or 10% FCS-DMEM medium. Approximately 24-26 h post-transfection, 
cells were washed as previously described (Bunn et al., 2001) and fixed in 3.7% 
formaldehyde. Coverslips were then mounted with Fluoro-Gel II containing 
DAPI onto glass slides. Protein distribution was analyzed using a Nikon Plan 
Apo 40x/0.95 objective on a Nikon ECLIPSE TE 2000-E fluorescence 
microscope and fluorescence emittance was facilitated by the following filter 
sets: Nikon Ultraviolet Excitation via UV-2E/C filter for DAPI/nuclei visualization; 
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Blue Excitation via B-2E/C filter block for GFP/FITC visualization; and Red 
Excitation via T-2E/C filter for mCherry/TRITC. A CoolSNAP HQ2 CCD camera 
(Photometrics, Tucson, AZ) allowed image capture and NIS-Elements AR 
software (Nikon) was used for analysis. Prior to analysis, slides were blinded by 
members of the lab to ensure scoring was performed without knowledge of 
treatment. Regions of interest (ROI) were positioned inside both the nucleus 
and cytoplasm of cells and fluorescence intensity was recorded for each. Three 
biological replicates with a minimum of 100 ROI-analyzed cells were recorded 
per transfection combination of TR subtypes with MED1. Relative nuclear to 
cytoplasmic (N/C) distribution and analysis was then calculated and normalized 
for corresponding biological replicates in Excel. Cotransfected ratios were 
normalized against the corresponding single transfection, where cotransfected 
TR would be normalized against the TR individually transfected under the same 
conditions. A ratio greater than a normalized value of 1 was interpreted as 
having a more nuclear distribution, while less than one indicated a greater 
distribution of protein in the cytoplasm. A student’s T-test was used to calculate 
p-values and determine significance. 
Confocal Fluorescence Recovery After Photobleaching (FRAP) – Eight hours 
post-transfection, transfection mixtures were replaced with the respective 10% 
FBS-MEM or 10% FCS-DMEM medium. Twenty three to twenty nine hours 
post-transfection, cells were washed with Dulbecco’s phosphate buffered saline 
(D-PBS). Cells were then incubated in MEM-α medium containing 50 μg/mL 
cycloheximide, 50 units/mL penicillin, and 50 μg/mL streptomycin for the 
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duration of the assay. After the addition of MEM-α, plates were incubated in an 
OkoLab Incubation System (Warner Instruments, Inc., Hamden, CT) which 
maintained conditions of 37°C and 5% CO2. To verify consistency of treatment 
results between the 6 h period, each treatment was assessed at the 23 h, 26 h, 
and 29 h intervals for the three biological replicates. A Nikon A1Rsi confocal 
microscope Ti-E-PFS (Nikon Inc., Melville, NY) with a 60x oil objective was 
utilized for all FRAP experiments. The 488-nm line of krypton-argon laser with 
a band-pass of 525/50 nm emission filter was used for GFP detection, while the 
561-nm line with a band-pass emission filter was used for mCherry detection. A 
solid-state 405-nm line of laser with a band-pass 450/50 emission filter was 
used exclusively for photobleaching. The “Perfect Focus System” (PFS) was 
applied during the duration of the experiments. Both acquisition and 
photobleaching were coordinated within NIS-Elements AR (Nikon). Using the 
stimulation module of NIS-Elements, the total experimental time for the assay 
was ~35 s. This was divided into a 5 s “pre-bleach” acquisition phase at ~2-3% 
laser power, 1 s of photobleaching at 100% laser power, and a post-bleach 
acquisition phase, again, at 2-3% laser power. All image acquisition was 
conducted through resonant scanning. The poor signal to noise ratio associated 
with both resonant scanning and low laser power was corrected by line 
averaging. Data from three biological replicates of 20 nuclei from separate cells 
were recorded for each TR isoform, MED1 variant, and cotransfection 
combination between the two. 
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FRAP data were normalized using a modified strategy presented by Phair et al. 
(2003). Equation 1 shows full normalization of fluorescence, Ifull, as a function 
of time, where Idouble norm represents the background-corrected, double 
normalization of fluorescence and tpostbleach is the background-corrected value at 
the time point immediately after bleaching has terminated. Further description 
of the double normalization is outlined by Phair et al. (2003). Effectively, the 
data were normalized from 0 – 1, where 0 was the lowest relative intensity, 
directly after the bleaching phase, and 1 was the point of greatest post-bleach 
recovery. 
𝐼(𝑡)𝑓𝑢𝑙𝑙 =  
𝐼(𝑡)𝑑𝑜𝑢𝑏𝑙𝑒 𝑛𝑜𝑟𝑚−𝐼(𝑡𝑝𝑜𝑠𝑡𝑏𝑙𝑒𝑎𝑐ℎ)𝑑𝑜𝑢𝑏𝑙𝑒 𝑛𝑜𝑟𝑚
1−𝐼(𝑡𝑝𝑜𝑠𝑡𝑏𝑙𝑒𝑎𝑐ℎ)𝑑𝑜𝑢𝑏𝑙𝑒 𝑛𝑜𝑟𝑚
 (1) 
Normalized data were then used to calculate the rate of recovery for each 
treatment. The recovery rate, post-bleach fluorescence recovery over time to 
equilibrium, was used as the primary measurement to evaluate changes in 
mobility. The normalized data were also used to estimate a half-time/Thalf value, 
or the time required for half of the total fluorescence to recover back into the 
bleached region. As our data were normalized to 1, we recorded the half-time 
as the time that elapsed between the end of the bleaching phase and the point 
at which 50% recovery occurred directly on the full-normalized recovery curve. 
Aside from Thalf, we also calculated the mobile and immobile fractions to support 
our understanding of mobility dynamics. The mobile fraction is represented in 
Equation 2 
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𝐹𝑚  =  
𝐼(𝑡𝑒𝑞) − 𝐼(𝑡𝑝𝑜𝑠𝑡𝑏𝑙𝑒𝑎𝑐ℎ)
𝐼(𝑡𝑝𝑟𝑒)− 𝐼(𝑡𝑝𝑜𝑠𝑡𝑏𝑙𝑒𝑎𝑐ℎ)
 (2) 
where Fm, is the mobile fraction, 𝐼(𝑡𝑒𝑞) is the full normalized intensity at which 
equilibrium on the recovery is reached, 𝐼(𝑡𝑝𝑟𝑒) is defined by the intensity pre-
bleach, and 𝐼(𝑡𝑝𝑜𝑠𝑡𝑏𝑙𝑒𝑎𝑐ℎ) is the intensity at time (t), directly after bleaching. 
Subsequently, the immobile fraction Fi can be calculated using Equation 3 
𝐹𝑖 =  1 –  𝐹𝑚 (3) 
Induction of MED1 Phosphorylation – Eight hours post-transfection, transfection 
mixtures were replaced with 10% Charcoal Stripped FBS (Gibco) MEM, or CS-
MEM, and/or either human epidermal growth factor, EGF (Gibco), or T3 
(Sigma). T3 and EGF were supplemented at previously described 
concentrations of 100 nM and 100 ng/ml, respectively (Bunn et al., 2001; 
Pandey et al., 2005). Twenty four to twenty six hours post-transfection, samples 
were then prepared and analyzed using the appropriate methods described for 
either FRAP or N/C nucleocytoplasmic scoring. 
Leptomycin B and Dexamethasone Treatment – FRAP assays performed on 
cells expressing mCherry-v-ErbA were supplemented with 5 ng/mL of 
Leptomycin B (Sigma) ~45 minutes prior to analysis. Cells transfected with 
GFP-tagged GR were treated with dexamethasone (Sigma) at a final 
concentration of 1 μM and incubated for ~30 minutes prior to analysis. Optimal 
minimum incubation times were determined separately using time lapse 
imaging. Directly after treatments were added, samples were transferred to the 
40
confocal microscope setup (Confocal Fluorescence Recovery After 
Photobleaching (FRAP)) and monitored for the accumulation of fluorescent 
protein in the nuclei of multiple cells. When fluorescent signal comparable to 
previously documented nuclear-localized protein samples, such as mCherry-
TRα1 or GFP-MED1, was reached, the minimum incubation period was 
achieved. 
Validation of MED1 Knockout and Phosphorylation 
HeLa cells and MEFs were seeded at 8.0 x 105 cells per 100 mm dish. HeLa 
(phosphorylation assay) and MEF (knockout validation) lysates were prepared 
48 h after cells were plated. Protein concentrations were measured using a 
Nano Drop (ND-1000 Spectrophotometer. 40 – 50 μg of protein were analyzed 
per lane. Western blot was performed as previously described (Subramanian et 
al., 2015). Antibodies were used with the following concentrations: anti-GAPDH 
(Santa Cruz Biotechnology Inc, Dallas, TX), 1:5000; anti-MED1 (Abcam), 1:500; 
anti-phosphothreonine (Abcam), 1:125; horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG (GE Healthcare Life Sciences), 1:25,000; 
HRP-sheep anti-mouse IgG (GE Healthcare Life Sciences), 1:25,000. Protein 
size was confirmed using Pre-Stained Kaleidoscope Protein Standards (Bio-
Rad, Hercules, CA). X-ray films were quantified by scanning densitometry using 
NIH ImageJ software. 
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RESULTS 
Overexpression of MED1 increases nuclear retention of TRβ1 and v-ErbA. 
Previous studies have determined that although TR localizes primarily to the 
nucleus, there is definitive shuttling between the nucleus and cytoplasm, as well 
(Bunn et al., 2001). The constitutive presence of TR in the nucleus points to 
regulatory factors that promote nuclear retention of TR. Here, we investigated 
the possibility that MED1, a transcriptional coactivator, plays a key role in TR 
nuclear retention. 
To determine if overexpression of MED1 altered the localization of TRα1 
and TRβ1, HeLa cells were transfected with either mCherry-TR or GFP-MED1 
individually and compared to cells cotransfected with mCherry-TR and GFP-
MED1. Each biological replicate contained a sample with mCherry-tagged TR, 
GFP-MED1, and one with TR and MED1 cotransfected. The single transfections 
were used as controls to normalize the fluorescence intensity of cotransfections 
for each replicate, and to calculate the comparative N/C ratio, to determine 
whether there were statistically significant differences in localization between 
treatments. As a negative control, we performed the same individual 
transfections and cotransfections, using a truncated form of MED1 (tMED1), 
which lacks the RBDs of wild type MED1 which interact with the LBD of TR. We 
predicted that overexpressing full-length MED1 would lead to a greater 
distribution of both TRα1 and TRβ1 in the nucleus, while overexpressing the 
truncated MED1 would have no effect on the distribution pattern of TR. As 
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predicted, when cotransfected with tMED1, there was no significant change in 
localization of TR (data not shown). 
Consistent with previous studies (Zhu et al.,1998; Bunn et al., 2001; Roggero et 
al., 2016), TRα1 was localized almost entirely to the nucleus, with only a small 
population of cells (<10%) having a cytosolic population of TRα1 (Fig. 1), 
whereas TRβ1 showed a greater cytosolic distribution relative to TRα1 (Fig. 2). 
When TRα1 was cotransfected with MED1, we observed no significant change 
in TRα1’s localization (p=0.299) (Fig. 1). However, cotransfection of MED1 and 
TRβ1 caused a significant shift toward a greater nuclear localization of TRβ1 
(p=0.004) (Fig. 2), suggesting that MED1 promotes TR nuclear retention. Based 
on this shift towards greater nuclear retention of TRβ1 in the presence of MED1, 
it seems likely that nuclear retention of TRα1 was also increased. However, due 
to the already robust localization of TRα1 in the nucleus at steady state, even 
without overexpression of MED1, it was not possible to detect enhanced 
retention. 
In our earlier reports, we have shown that in most cells v-ErbA, the oncogenic 
homolog of TR, has a predominantly cytoplasmic distribution (Bunn et al., 2001; 
Bonamy et al., 2005; DeLong et al., 2004). Individual transfection of mCherry-
v-ErbA reaffirmed this finding (Fig. 3). In contrast, we found that overexpressing 
MED1 led to a more whole-cell distribution of v-ErbA; there was a significant 
increase in the relative N/C ratio (p=0.001) (Fig. 3), suggesting that MED1 also 
promotes nuclear retention of v-ErbA. 
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Cotransfecting MED1 with TR subtypes alters the nuclear distribution of MED1. 
Although our primary interest is with the subcellular localization of TR, we also 
analyzed the distribution pattern of MED1 alone and when cotransfected with 
TR subtypes. Previous reports confirmed the predicted nuclear localization of 
MED1 (Cui et al., 2012; Fondell, 2013; Pandey et al., 2005), and there is no 
evidence yet of rapid nucleocytoplasmic shuttling of MED1 (Allison lab 
unpublished observations). Therefore, we predicted our nucleocytoplasmic 
scoring method would show MED1 has near-absolute nuclear localization. 
Here, we verified the distinct nuclear localization of MED1 when transfected 
alone (see Figs. 1 – 3). Interestingly, nearly half of the cells transfected with only 
GFP-MED1 contained nuclei with several MED1-aggregates of either 
approximately equal size or far larger aggregates that encompassed up to half 
of the nucleus (see Fig. 3, “MED1 single” panel). Cotransfecting any of the TR 
variants with MED1 resolved these nuclear aggregates. Furthermore, we 
discovered that overexpressing MED1 with TRα1, TRβ1, or v-ErbA, 
simultaneously, resulted in a significant shift towards a more cytosolic 
localization of MED1 (p<0.001, p<0.05, and p<0.001, respectively). The 
physiological relevance of these observation remains to be determined. 
Overexpression of MED1 alters the intranuclear mobility of TRβ1. The reported 
role of MED1 as a coactivator of TR-regulated genes (Belakavadi et al., 2008; 
Fondell, 2013; Pandey et al., 2005) led us to hypothesize that overexpressing 
MED1 would increase TR’s residence time bound to DNA. As a result, we 
predicted that overexpression of MED1 would lead to a decrease in TR 
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intranuclear mobility. To analyze intranuclear mobility, we used a variation of 
FRAP, termed strip-FRAP. Strip-FRAP was selected as the method of choice 
based on the even distribution of TR in the nucleus. In this method, a small strip 
through the nucleus is photobleached and mobility is monitored by the recovery 
of fluorescent proteins into the bleached strip. 
To confirm the validity of our FRAP experiments, we first employed a 
series of strategies aimed at improving accuracy. The observed diffusional rate 
of TR from pilot studies emphasized the efficacy of strip-FRAP to take 
advantage of horizontal scan frequency. In this set-up, a “stimulation line” region 
of interest (ROI) was positioned within the nucleus of a cell and served as the 
targeted region for 1 s of photobleaching. Prior to data collection, several 
constraints were considered and applied to our strip-FRAP setup, which have 
previously been advised by others (Weiss, 2004; Yang et al., 2010). First, to 
ensure sufficient bleaching along the z-axis, we conducted strip-FRAP on fixed 
cell samples and acquired 3-dimensional “z-stacks” to quantify the bleaching 
depth (data not shown). Here, we consistently confirmed bleaching depths 
greater than the cell’s z-dimensional width and thus, verified a bleach depth 
greater than the cell width along the z-axis. Second, to minimize for any error 
created by lack of uniformity in diffusion from the x and y planes, sample 
selection was confined to nuclei with as symmetrical morphology as HeLa cell 
nuclei allowed. Third, brief studies were completed using ROIs at variable 
regions in nuclei to conclude that TR was evenly and diffusely distributed within 
nuclei. To further account for this, the stimulation/bleaching ROI was adjusted 
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to a symmetrical position in the nuclei along the midline. Similarly, cell/nucleus 
selection took into consideration the relative bleach area to total cell volume 
ratio. Finally, to reduce the concentration of protein diffusing into the bleach 
region during the bleaching phase, we combined resonant scanning and the 
lowest possible bleach interval allowable for considerable photobleaching. 
These adjustments allowed for a frame rate of ~15 images per second. PFS 
was also applied to stabilize the sample’s focal position during FRAP and 
compensated for otherwise needing to increase pinhole aperture to account for 
drift. FRAP results with displaced ROIs from the intended positioning in nuclei, 
due to drift, that occurred pre-bleach, and therefore couldn’t be accounted for 
with post-analysis tracking adjustments, were discarded. 
After validating the use of strip-FRAP, we first compared cells expressing 
mCherry-TRα1 to cells co-expressing mCherry-TRα1 and GFP-MED1 
simultaneously (Fig 4A). The resulting fluorescence intensity data were 
normalized using Eq. 1. Data normalization then allowed us to determine the 
recovery rate, mobile fraction, immobile fraction, and estimated Thalf based on 
the FRAP curves. For TRα1 co-expressed with MED1, we observed no 
significant difference in any of these variables (p > 0.05) (Fig 4B, Table 1). 
In contrast, when conducting the same MED1 cotransfection assay with 
TRβ1, there was a significant reduction in the estimated Thalf and mobile fraction 
of TRβ1, and thus an increase in the immobile fraction (Table 1). p-values for 
mobile fraction/immobile fraction and estimated Thalf were 0.007 and 0.035, 
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respectively. mCherry-TRβ1 alone had a faster influx of signal directly after 
photobleaching resulting in close to complete recovery, while co-overexpressed 
TRβ1 did not show complete recovery (Fig. 5). 
Knockout of MED1 promotes export of TRα1 and TRβ1 into the cytoplasm. 
Given that MED1 is required for the expression of TR-regulated genes (Ito et 
al., 2000; Malik et al., 2004), we hypothesized that MED1 helps to anchor TR in 
the nucleus. Our findings from overexpression of MED1 suggest that MED1 
indeed plays a role in nuclear retention of TR subtypes. To build on our findings, 
we chose to analyze TR’s intracellular distribution in the absence of MED1. We 
anticipated that a greater cytoplasmic population of TR would be observed in 
null MED1/TRAP220-/- MEFs compared to wild-type MED1/TRAP220+/+ MEFs. 
These cell lines were provided by the Roeder lab who previously verified 
successful knockout of MED1 (Ito et al., 2000). Our Western blots to confirm 
knockout of MED1 in the TRAP220-/- cells were unsuccessful, likely because of 
time constraints for optimizing extraction and transfer of this very large protein 
(data not shown). 
After transfecting the null and wild-type MEF cell lines with TR expression 
plasmids, nucleocytoplasmic distribution was quantified using the previously 
described scoring method. Here, we show that mCherry-tagged TRα1 (Fig. 6) 
and TRβ1 (Fig. 7) have a significantly greater cytoplasmic population (lower N/C 
ratio) in TRAP220-/- MEFs, relative to their distribution patterns in TRAP220+/+ 
cells (p<0.01), suggesting that in the absence of MED1, nuclear retention of TR 
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is decreased. Not surprisingly, given the primarily cytoplasmic distribution of v-
ErbA in wild-type cells, no significant change in localization of v-ErbA was 
apparent in the TRAP220-/- MEFs (p = 0.30) (Fig. 8). 
Phosphorylation of endogenous MED1 does not affect localization of TRα1 and 
v-ErbA, but T3-induced MED1 phosphorylation reduces TRβ1 nuclear retention. 
As discussed earlier, it has been shown that MED1 is phosphorylated at specific 
threonine residues, and that phosphorylated MED1 is a more potent coactivator 
of TR-regulated genes (Pandey et al., 2005; Belakavadi et al., 2008). Based on 
our analysis of TR’s nucleocytoplasmic distribution in the presence and absence 
of MED1, we predicted that phosphorylated MED1 would increase retention of 
TR in the nucleus. To test this prediction, cells were incubated in charcoal-
stripped FBS media depleted of T3 and growth factors. We then stimulated the 
MAPK-ERK signaling pathway to trigger phosphorylation of MED1 using EGF 
or T3 (Pandey et al. 2005), and compared the resulting distribution patterns of 
TR to that of T3-depleted (-T3) cells. 
Contrary to our predictions, supplementing transfected cells with EGF 
had no effect on localization of mCherry-tagged TRα1, TRβ1, or v-ErbA (p>0.05 
for each) (Figs. 9 – 11). Treating TRα1 and v-ErbA-transfected cells with T3 
yielded similar outcomes. However, cells transfected with TRβ1 responded to 
T3 treatment by, unexpectedly, displaying a significant shift in TRβ1 towards the 
cytoplasm (p<0.001) (Fig. 10). The N/C values, before normalization, decreased 
from ≈ 6.5 to ≈ 4.0 with T3 treatment. It is known that proteasome-mediated 
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degradation of TR is more rapid in the presence of T3 (Bondzi et al., 2011), so 
it is possible that this change in distribution pattern results from altered protein 
turn-over, rather than direct interactions with MED1. 
Phosphorylation of MED1 has minimal effect on TRα1 and TRβ1 mobility. Based 
on the finding that phosphorylation of MED1 enhances its interaction with TR 
(Belakavadi et al., 2008; Pandey et al., 2005), we predicted that inducing this 
modification in MED1 would decrease intranuclear mobility of TR, as assessed 
by Strip-FRAP. Here, we found that the mobility of both TRα1 and TRβ1 was 
largely unaffected by treatment with either T3 or EGF. Intriguingly, however, 
when compared to T3-depleted conditions, we found that TRβ1 had a significant 
increase in its rate of recovery when treated with T3 (p < 0.05), whereas the 
mobile fraction of TRα1 in the presence of EGF decreased significantly (p < 
0.05) (Table 1). Interpretation of these findings will require further investigation, 
as they suggest more complex interactions with other nuclear factors and 
signaling pathways. 
Intranuclear mobility of GR confirms comparability of TR FRAP. Prior to this 
thesis research, mobility values for TR had not been previously defined. On the 
other hand, mobility of GR by FRAP assays has been extensively characterized 
(Carrero et al., 2003; Groeneweg et al., 2014; Meijsing et al., 2007). Previous 
characterization of GR allowed us to assess the comparability of our assay. To 
compare our own results of GR mobility against previously reported values, we 
treated cells expressing GFP-GR with dexamethasone to induce a nuclear 
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population of GR. FRAP was then performed and analyzed. While others have 
reported halftimes of greater than a few seconds for GR, we found that on 
average, GR’s halftime was ~0.74 seconds. Thus, our initial interpretation was 
that we were over-estimating mobility dynamics of proteins using our FRAP 
design. However, individual analysis of GR trials revealed two distinct 
populations of GR provoking a bimodally skewed distribution of our data. This 
phenomenon has recently been reported by a similar analysis of GR FRAP 
(Groeneweg et al., 2014). One GR state demonstrated a relatively fast halftime 
(~ 0.6 s) while another was much slower (~3.0 s) (Table 1). The latter is depicted 
in Figure 14A, and the former (data not shown) is both graphically and visually 
analogous to TRα1 or TRβ1 (see Figures 4 and 5).  
To examine additional parameters impacting intranuclear mobility, we 
also used FRAP to analyze a previously constructed expression vector 
containing TR’s hinge domain NLS (Mavinakere et al., 2012), which is 
abbreviated here as GFP-GST-GFP-NLS. Of the different attributes, the vector 
encodes a GFP-GST-GFP-tag allowing us to visualize its movement. Knowing 
that the GFP-GST-GFP-NLS fusion protein lacks the DBD domain present in 
TR, we predicted that an isolated NLS of TR would display greater intranuclear 
mobility than TR. In support of this, the GFP-GST-GFP-NLS fusion protein had 
a significantly faster rate of recovery than any TR subtype (p<0.001) (Fig. 14B, 
Table 1). Therefore, we conclude the comparability of our strip-FRAP 
experimental set-up with prior reports for other transcription factors. However, 
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future analysis of diffusional coefficients and model-fitting is needed to provide 
further support for this conclusion.  
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Figure 1. Overexpression of MED1 does not alter the nucleocytoplasmic distribution of TRα1. 
HeLa cells were transfected with either mCherry-TRα1 or cotransfected with mCherry-TRα1 and 
GFP-MED1. 24h post-transfection cells were analyzed using fluorescence microscopy. N/C ratios 
were determined for 3 replicates of 100 cells and the average, relative N/C ratio was calculated 
(normalized to the distribution in single-transfected cells. (Bottom) Compared to transfecting TRα1 
alone, co-overexpression with MED1 yielded no significant change in intracellular distribution of TRα1 
(p > 0.05). However, nuclear retention of MED1 was significantly reduced from cotransfection with TR
α1 (p < 0.001).  
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Figure 2. Overexpression of MED1 increases the nuclear retention of TRβ1. HeLa cells were 
transfected with either mCherry-TRβ1 or cotransfected with mCherry-TRβ1 and GFP-MED1. 24h 
post-transfection cells were analyzed using fluorescence microscopy. N/C ratios were determined for 
3 replicates of 100 cells and the average, relative N/C ratio was calculated (normalized to the 
distribution in single-transfected cells. (Bottom) Compared to transfecting TRβ1 alone,           
co-overexpression with MED1 increased the nuclear localization of TRβ1 (p < 0.01). Additionally, the 
retention of MED1 significantly decreased (p < 0.05).  
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Figure 3. Overexpression of MED1 increases the nuclear retention of v-ErbA. HeLa cells were 
transfected with either mCherry-v-ErbA or cotransfected with mCherry-v-ErbA and GFP-MED1. 24h 
post-transfection cells were analyzed using fluorescence microscopy. N/C ratios were determined for 
3 replicates of 100 cells and the average, relative N/C ratio was calculated (normalized to the        
distribution in single-transfected cells). (Bottom) Compared to transfecting v-ErbA alone, co-overex-
pression with MED1 increased the nuclear localization of v-ErbA (p < 0.01). Additionally, the retention 
of MED1 significantly decreased (p < 0.001).  
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Figure 4. Co-transfecting TRα1 with GFP-MED1 does not alter the intranuclear mobility of    
TRα1. HeLa cells were transfected with either mCherry-TRα1 or cotransfected with mCherry-TRα1 
and GFP-MED1. Strip-FRAP was conducted on nuclei from 20 separate cells using a stimulation 
bleaching line near the midline of the nuclei. 3 biological replicates were performed (n=3). Data were 
normalized and compared between TRα1 transfected alone (TRα1 single) and Cotransfected TRα1 
(Cotransfection). (A) Nuclei prior to bleach (pre-bleach), directly after bleaching terminated (bleach), 
1 second post-bleach (+1s), and at the end of the recovery (final). Scale bar is defined as 10μm. (B) 
Graphical representation of the FRAP recovery curves acquired from the 3 biological replicates. 
Comparison between TRα1 expressed alone and TRα1 cotransfected is shown 
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Figure 5. Co-transfecting TRβ1 with GFP-MED1 reduces the halftime and mobile fraction of 
nuclear TRβ1. HeLa cells were transfected with either mCherry-TRβ1 or cotransfected with   
mCherry-TRβ1 and GFP-MED1. Strip-FRAP was conducted on nuclei from 20 separate cells using a 
stimulation bleaching line near the midline of the nuclei. 3 biological replicates were performed 
(n=3). Data were normalized and compared between TRβ1 transfected alone (TRβ1 single) and 
Cotransfected TRβ1 (Cotransfection). (A) Nuclei prior to bleach (pre-bleach), directly after bleaching 
terminated (bleach), 1 second post-bleach (+1s), and at the end of the recovery (final). Scale bar is 
defined as 10μm. (B) Graphical representation of the FRAP recovery curves acquired from the 3 
biological replicates. Comparison between TRβ1 expressed alone and TRβ1 cotransfected is shown 
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Figure 6. Knockout of MED1 decreases the nuclear retention of TRα1. (A) Mouse embryonic 
fibroblasts (MEFs) were transfected with mCherry-TRα1. 24h post-transfection cells were analyzed 
using fluorescence microscopy. (B) N/C ratios were determined for 3 replicates of 100 cells and the 
average, relative N/C ratio was calculated (normalized to the distribution in wild-type cells). TRAP220 
+/+ MEFs expressing TRα1 had a greater nuclear distribution of TRα1 while an increase in             
cytoplasmic distribution is observed in the TRAP220 -/- (top). Comparison of the N/C ratios showed a 
decreased nuclear retention in the TRAP220 -/- MEFs compared to the TRAP220 +/+ (p < 0.05). 
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Figure 7. Knockout of MED1 decreases the nuclear retention of TRβ1. (A) Mouse embryonic 
fibroblasts (MEFs) were transfected with mCherry-TRβ1. 24h post-transfection cells were analyzed 
using fluorescence microscopy. (B) N/C ratios were determined for 3 replicates of 100 cells and the 
average, relative N/C ratio was calculated (normalized to the distribution in wild-type cells. TRAP220 
+/+ MEFs expressing TRβ1 had a greater nuclear distribution of TRβ1 while an increase in cytoplas-
mic distribution is observed in the TRAP220 -/- (top). Comparison of the N/C ratios showed a 
decreased nuclear retention in the TRAP220 -/- MEFs compared to the TRAP220 +/+ (p = 0.001). 
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Figure 8. Knockout of MED1 has no effect on the nuclear retention of v-ErbA. (A) Mouse       
embryonic fibroblasts (MEFs) were transfected with mCherry-v-ErbA. 24h post-transfection cells were 
analyzed using fluorescence microscopy. (B) N/C ratios were determined for 3 replicates of 100 cells 
and the average, relative N/C ratio was calculated (normalized to the distribution in wild-type cells). 
Both the TRAP220 +/+ and TRAP220 -/- MEFs expressing mCherry-v-ErbA exhibited a primarily 
cytoplasmic localization. Comparison of the N/C ratios for both MEFs revealed no significant           
difference in nuclear retention of v-ErbA (p > 0.05). 
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Figure 9. Phosphorylation of MED1 does not affect the nuclear retention of TRa1. (A) 
HeLa cells were transfected with mCherry-TRα1. 8h after transfection, cells were incubated in 
charcoal-stripped FBS and EGF or T3. 24 hours post-transfection, nucleocytoplasmic            
distribution was assessed. (B) N/C ratios were determined for 3 replicates of 100 cells and the 
average, relative N/C ratio was calculated (normalized to the distribution in -T3 cells). Induction 
of MED1 phosphorylation with T3 and EGF did not have a significant effect on the retention of 
TRa1 (p > 0.05).
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Figure 10. Phosphorylation of MED1 by T3 treatment increases amount of TRβ1 in the 
cytoplasm. (A) HeLa cells were transfected with mCherry-TRβ1. 8h after transfection, cells 
were incubated in charcoal-stripped FBS and EGF or T3. 24 hours post-transfection,              
nucleocytoplasmic distribution was assessed. (B) N/C ratios were determined for 3 replicates of 
100 cells and the average, relative N/C ratio was calculated (normalized to the distribution in 
-T3 cells). Induction of MED1 phosphorylation with both by EGF stimulation of MAPK-ERK 
signaling failed to have a significant effect on the retention of TRa1 (p > 0.05). However, 
treatment of TRβ1-expressing cells with T3 caused a decrease in nuclear retention, causing a 
shift of protein towards the cytoplasm (p < 0.001). Primarily nuclear localization of TRβ1 was 
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Figure 11. Phosphorylation of MED1 does not affect the nuclear retention of v-ErbA. (A) 
HeLa cells were transfected with  mCherry-v-ErbA. 8h after transfection, cells were incubated in 
charcoal-stripped FBS and EGF or T3. 24 hours post-transfection, nucleocytoplasmic            
distribution was assessed. (B) N/C ratios were determined for 3 replicates of 100 cells and the 
average, relative N/C ratio was calculated (normalized to the distribution in -T3 cells). Induction 
of MED1 phosphorylation with both T3 and EGF did not have a significant effect on the           
retention of v-ErbA (p > 0.05).
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Figure 12. EGF-induced phosphorylation of MED1 reduces the mobile fraction of TRα1 HeLa 
cells were transfected with mCherry-TRα1. 8h after transfection, cells were incubated in 
charcoal-stripped FBS and EGF or T3. Strip-FRAP was performed on 3 biological replicates of 20 
cells each. (A) Nuclei prior to bleach (pre-bleach), directly after bleaching terminated (bleach), 1 
second post-bleach (+1s), and at the end of the recovery (final). Scale bar is defined as 10μm. (B) 
Graphical representation of the FRAP recovery curves acquired averages between the replicates 
Comparison between TRα1 -T3 (black), TRα1 +T3 (blue), and TRa1 +EGF (red) is displayed. 
Treatment with EGF caused a reduction in mobile fraction from ~93% in TRα1 -T3 to ~82%             
(p = 0.01).
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Figure 13. T3-induced phosphorylation of MED1 increases the rate of TRβ1 recovery. HeLa 
cells were transfected with mCherry-TRβ1. 8h after transfection, cells were incubated in 
charcoal-stripped FBS and EGF or T3. Strip-FRAP was performed on 3 biological replicates of 20 
cells each. (A) shows nuclei prior to bleach (pre-bleach), directly after bleaching terminated (bleach), 
1 second post-bleach (+1s), and at the end of the recovery (final). Scale bar is defined as 10μm. (B) 
Graphical representation of the FRAP recovery curves acquired averages between the replicates 
Comparison between TRβ1 -T3 (black), TRβ1 +T3 (blue), and TRβ1 +EGF(red) is displayed. 
Treatment with T3 caused an increase in the rate of TRβ1 recovery within the bleached region        
(p < 0.05).
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Figure 14. GFP-GR and GFP-NLS FRAP shows TRa1’s NLS has greater mobility than 
full-length TRa1. HeLa cells were transfected with either mCherry-TRα1, GFP-GR, or GFP-NLS. 
Strip-FRAP was conducted on nuclei from 20 separate cells using a stimulation bleaching line near 
the midline of the nuclei. 3 biological replicates were performed (n=3). Data were normalized and 
compared. (A) shows nuclei expressing GFP-GR prior to bleach (pre-bleach), directly after     
bleaching terminated (bleach), 1 second post-bleach (+1s), and at the end of the recovery (final). Of 
two mobility states for GFP-GR, the slower is displayed here. (B) Graphical comparison between 
FRAP of mCherry TRa1 (red) and GFP-NLS (green). GFP-NLS has a significantly faster rate of 
recovery than native TRa1 (p < 0.001). 
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Table 1. FRAP measurements for TRa1 and TRβ1. Slope, mobile and immobile fraction, and halftime          
measurements for TRa1 and TRβ1 under various conditions. Data were calculated from FRAP curves for each 
separate condition. TR “Single” indicates cells expressing only exogenous TR, while “Cotransfected” indicates 
cells cotransfected with MED1, as well. MED1 phosphorylation assays are represented by the data for TRa1 or TR
β1 ±T3/EGF.
 
Treatment Slope Mobile Frac�on Immobile Frac�on Half-�me 
TRα1 Single 0.011 ± 0.0003 0.946 ± 0.03 0.054 ± 0.03 1.01s ± 0.18s 
TRα1 Cotransfected 0.012 ± 0.0009 0.922 ± 0.05 0.078 ± 0.05 1.21s ± 0.42s 
TRα1 -T3 0.013 ± 0.0014 0.932 ± 0.02 0.068 ± 0.02 1.26s ± 0.19s 
TRα1 +T3 0.011 ± 0.0008 0.910 ± 0.02 0.089 ± 0.02 1.17s ± 0.21s 
TRα1 +EGF 0.011 ± 0.0007 0.822 ± 0.07 0.178 ± 0.07 1.79 ± 0.92s 
TRβ1 Single  0.012 ± 0.0007 0.999 ± 0.03 0.0006 ± 0.03 0.92s ± 0.08s 
TRβ1 Cotransfected 0.013 ± 0.0006 0.968 ± 0.01 0.032 ± 0.01 1.20s ± 0.13s 
TRβ1 -T3 0.014 ± 0.0007 0.970 ± 0.01 0.030 ± 0.01 1.37s ± 0.17s 
TRβ1 +T3 0.013 ± 0.0004 0.976 ± 0.02 0.023 ± 0.02 1.10s ± 0.17s 
TRβ1 +EGF 0.013 ± 0.0009 0.988 ± 0.01 0.012 ± 0.01 1.08s ± 0.12s 
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DISCUSSION 
In our prior studies, we showed that TR is capable of nucleocytoplasmic 
shuttling (Bunn et al., 2001). Our efforts further revealed the signal sequences 
that are responsible for TR’s shuttling capability, as well as determining that TR 
follows both CRM1-dependent and CRM1-independent export pathways 
(Grespin et al., 2008; Mavinakere et al., 2012). Recently, we’ve identified the 
various exportins that facilitate CRM1-dependent export and the importins 
responsible for TR’s entry into the nucleus (Roggero et al., 2016; Subramanian 
et al., 2015). Here, we extend our understanding of the fine balance between 
nuclear import, nuclear retention, and nuclear export of TR, by providing 
evidence that MED1 plays a key role in regulating the nuclear retention of TR 
variants. 
We showed that overexpression of MED1 in HeLa cells leads to a greater 
nuclear distribution of TRβ1 and v-ErbA, and decreases the Thalf and mobile 
fraction of TRβ1. On the other hand, knockout of MED1 in MEFs resulted in a 
greater cytoplasmic distribution of TRα1 and TRβ1 relative to the distribution 
pattern in cells expressing MED1. We also show that T3-induced 
phosphorylation of MED1 causes a reduction in nuclear retention of TRβ1 and, 
also, increases the intranuclear mobility of TRβ1 relative to T3-depleted 
conditions. Collectively, our results provide evidence that MED1 plays a 
definitive role in regulating nuclear retention of TR subtypes. 
MED1-regulated TR retention is dependent on MED1 
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Prior to our analysis, MED1 had previously been shown to play an essential role 
in TR-controlled gene expression. In fact, knockout of MED1 causes dysfunction 
in TR’s regulation to an extent that resulted in embryonic lethality in mice (Ito et 
al., 2000). The significance of the interaction between MED1 and TR led us to 
propose that MED1 is also an important component governing TR’s nuclear 
retention. Using a combination of strip-FRAP and nucleocytoplasmic scoring, 
we determined that MED1 is involved in TR nuclear retention. The direct 
interaction between TR subtypes and MED1 is supported by our findings from 
overexpression assays. When overexpressing MED1 by itself, distinct 
aggregates of MED1 were spread diffusely throughout the nucleus. However, 
when either TRα1, TRβ1, or v-ErbA was co-expressed, the MED1 aggregates 
no longer formed, suggesting that the MED1 aggregates were resolved 
following interaction with the exogenous TR. 
Interestingly, MED1 overexpression and knockout led to different results 
for TRα1, TRβ1, and v-ErbA. Overexpression of MED1 caused TRβ1 and v-
ErbA to shift towards significantly greater nuclear retention. TRβ1 and v-ErbA 
both have a higher detectable cytosolic population of protein relative to TRα1. 
This difference in distribution is thought to result, in part, from TRα1’s NLS-2 in 
the A/B domain which is not present in TRβ1 and is mutated in v-ErbA 
(Mavinakere et al., 2012). As noted in the results, we conclude that our 
nucleocytoplasmic scoring method was more efficient in capturing a difference 
in retention for TRβ1 and v-ErbA rather than TRα1, because of TR’s primarily 
nuclear localization. Likewise, when performing similar analysis with MED1 
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knocked out, where we anticipated a reduction in retention and a greater 
distribution in the cytoplasm, no significant change in v-ErbA, a primarily 
cytosolic protein, was observed. However, for TRα1 and TRβ1, which are 
primarily nuclear in wild-type cells, we did observe a cytosolic shift in TRα1 and 
TRβ1 distribution in MED1-null cells. 
As mentioned, TRα1 and TRβ1 carry NES-H12 in their LBDs, a motif that 
is naturally deleted from v-ErbA (Mavinakere et al., 2012). Extrapolating off our 
current MED1 knockout results, we propose a model involving competition 
between MED1 and exportins 4, 5, or 7 to balance nuclear retention and export 
of TR. Therefore, by removing MED1 from this competition in TRAP220-/- MEFs, 
it’s likely that the greater cytoplasmic distribution of TR relative to TRAP220+/+ 
MEFs that we observed is due to increased interaction between NES-H12 of 
TRα1 and TRβ1 and exportins 4, 5, or 7. On a different note, we’ve also shown 
that v-ErbA not only localizes predominantly to the cytoplasm, but that it also 
dimerizes with TRα1 and causes a fraction of TRα1’s nuclear population to 
mislocalize to the cytoplasm (Bonamy et al.; Bunn et al., 2001). While TRα1 has 
been shown to interact directly with MED1, v-ErbA’s interaction with MED1 is 
still yet to be tested. Considering this, we hypothesize the possibility of an 
indirect interaction of v-ErbA with MED1 which causes the observed shift in v-
ErbA towards the nucleus when MED1 is overexpressed. Ultimately, since v-
ErbA is still dimerizing with the low endogenous TRα1 concentration in the 
nucleus, it’s possible that overexpressing MED1 leads to greater association 
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with this dimer through binding TRα1 and effectively reduces the nuclear export 
of v-ErbA. 
Phosphorylated MED1 variably affects retention of TRα1 and TRβ1 
Our interest in phosphorylation of MED1 was considered in light of evidence for 
MED1-stimulated increases in TR-dependent transcription (Pandey et al., 
2005). Interestingly, MED1 phosphorylation also leads to the upregulation of 
MED1 directly, which ultimately accelerates various forms of cancer (Jin et al., 
2013; Vijayvargia et al., 2007). Contrary to our prediction that phospho-MED1 
would enhance nuclear retention of TR, we found that after stimulating 
phosphorylation of MED1, the retention of TRα1, TRβ1, and v-ErbA was 
unaffected. As an exception to this trend, addition of T3 caused decreased 
nuclear retention of TRβ1 compared to the T3-depleted conditions in our 
nucleocytoplasmic scoring assay. On the contrary, we previously reported that 
addition of T3 to Xenopus (amphibian) oocytes resulted in greater nuclear 
retention of TRα1 but this effect was not observed in mammalian cells cultured 
in the presence or absence of T3 (Bunn et al., 2001). The disagreement 
between our past findings and the results in this study suggests different 
responses to thyroid hormone in Xenopus models compared to our HeLa-
mammalian cell approach. Regardless, the variability in response between 
TRα1 and TRβ1 is puzzling and requires further analysis. We recently 
conducted a pilot study using longer incubation periods for T3 and EGF which 
provoked a sharper decrease in mobile fraction (data not shown). However, 
70
cells were incubated significantly longer than others have used to induce MED1 
phosphorylation (Belakavadi et al., 2008; Kim et al., 2017; Pandey et al., 2005). 
Questions surrounding cytotoxicity and cell viability using this extended 
treatment must be addressed in future work to justify the cogency of an 
alternative approach. 
In addition to the scoring analysis, using FRAP to probe the effects of 
phospho-MED1 TR mobility yielded similar unexpected outcomes. In 
disagreement with our predictions, T3-stimulated phosphorylation of MED1 
caused an increase in the mobility of TRβ1. This result was consistent with a 
reduction in TRβ1 nuclear retention from nucleocytoplasmic scoring under the 
same conditions. Similarly, MED1 phosphorylation had minimal effect on the 
nuclear mobility of TRα1. However, we did observe that EGF treatment 
independently affected TRα1’s dynamics, although, studies have shown both 
EGF and T3 induce MED1 phosphorylation with similar efficiency (Belakavadi et 
al., 2008). Aside from altering the mechanics of our experiment, it is possible 
that intrinsic cell-control mechanisms are protecting against the harmful effects 
of MED1 upregulation. Phosphorylation of MED1 has been shown to increase 
its half-life and thus contribute to its overexpression (Belakavadi et al., 2008). 
Therefore, its plausible that in the presence of a greater phospho-MED1 
population, control mechanisms are induced that subsequently degrade the 
protein, as well. 
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Recently, however, this stabilization of MED1 has generated much 
interest for its contribution to the development and progression of several 
cancers, including breast, lung, and prostate cancer (Chen et al., 2011; Cui et 
al., 2012; Jin et al., 2013; Kim et al., 2012; Vijayvargia et al., 2007). MED1 
concentration and phosphorylation are surveilled by microRNA-205 (miR-205), 
a potent inhibitor of MED1 and its phosphorylation-induced stabilization, and 
which assists in MED1 mRNA degradation (Hulf et al., 2012; Jin et al., 2013; 
Mouillet et al. 2012). Therefore, it has been proposed that miR-205 regulates 
the proper intracellular concentration of MED1. Interestingly, miR-205 is 
constitutively upregulated in cervical cancer cells (Xie et al., 2012). Based on 
the origin of HeLa cells, this would point to the prospect of these cells 
upregulating the production of miR-205, under standard conditions. By 
artificially stabilizing the half-life of MED1 through phosphorylation, we may also 
have been simultaneously inducing an even higher concentration of the 
endogenously upregulated miR-205. Effectively, this would amplify the 
regulation applied to HeLa-endogenous MED1. Targeted for phosphorylation 
through both ERK and AKT signaling, phospho-MED1 also bridges these 
pathways to several downstream targets which are typically kept under tight 
regulation and may contribute to a rapid degradation of the phosphoprotein (Jin 
et al., 2013). Taken together, this would help to explain a difference between 
the observations made with our overexpression and phosphorylation assays 
due to our reliance on endogenous MED1 concentration for analysis of the 
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phosphorylation assay rather than introducing an influx to counteract miR-205, 
as we may have unknowingly done with the overexpression studies. 
In summary, either overexpressing MED1 during phosphorylation 
analysis or performing the phosphorylation assays in an alternative cell line, as 
others have done (Chen et al., 2011; Jin et al., 2013; Kim et al., 2017), will 
remove the possibility of this complication. Additionally, comparing the relative 
concentration of miR-205 in untreated, MED1-overexpressed, and upregulated 
phospho-MED1 cells will provide additional insight into how cells balance MED1 
levels to regulate downstream targets such as TR and its nucleocytoplasmic 
distribution. 
 Our findings with MED1 provide an exciting prospect toward 
understanding TR disease pathogenesis. Reports show that some of the 
several mutations in TRβ1 that contribute to RTH occur in the LBD, and more 
specifically, within helix 12 (Yen et al., 2001). In combination with knowing that 
MED1 interacts with helix 12 of TR and our findings reported here, it is possible 
that such a mutation may disrupt the MED1-TR interaction and generate 
mislocalization of the receptor. However, one study revealed that MED1 is 
curiously only found in a small subset of cells (Zhang et al., 2005). This suggests 
a distinct role for MED1 in TR retention for some cell types, but additional 
mechanisms may be in place to adequately maintain its localization. 
Regardless, we conclude here that TR’s nuclear retention is regulated, in part, 
by its interaction with MED1. 
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CHAPTER 3: GENERAL DISCUSSION 
The research presented in this thesis provides evidence for MED1 as a regulator 
of TRα1, TRβ1, and v-ErbA nuclear retention. While previous literature explains 
how MED1 influences the transcriptional activity of genes controlled by TR, we 
expand on this by showing how the interaction is involved in dictating the 
subcellular distribution of TR. Our data show that in the presence of higher 
levels of MED1, there is a significant increase in nuclear-localized TRβ1 and v-
ErbA. Similarly, in the absence of MED1, TRα1 and TRβ1 distribute more to the 
cytoplasm. None of these localization changes led to entire sequestration to the 
nucleus or cytoplasm, however. This is suggestive of either an orchestrated 
balance, or competition for TR-binding between exportins and MED1 to control 
TR’s nuclear retention. Additionally, this agrees with the likelihood of several 
other factors, external to the described exportin-MED1 relationship, that 
contribute to this regulation. Also, mobility of TR variants is variably affected by 
EGF and T3-induced phosphorylation of MED1 by MAPK-ERK. We offered 
several reasons to account for inconsistencies, but ultimately, TR interacts with 
other intranuclear proteins that may have more resolute control over TR’s 
mobility. 
Understanding external factors affecting TR’s intranuclear mobility 
remains important. Inducing decreases in mobility of transcription factors has 
been shown to be an excellent approach for revealing interactions that affect 
not only localization but also transcriptional activity. Using FRAP to study the 
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intranuclear mobility of other receptors, such as the estrogen receptor, has 
revealed multiple interactions that modify its interplay with DNA (Stenoien et al., 
2001). Identifying these protein interactions which promote TR’s residence time 
with DNA and decrease TR’s intranuclear mobility will isolate the mechanisms 
controlling its nuclear retention. Ultimately, this will also help to understand 
where MED1 fits into the dynamics. As an example, prior studies suggest that 
the nuclear retention of TRβ is dependent on NCoR and dimerization with RXR 
(Baumann et al., 2001). As a corepressor of TR, NCoR works antagonistic to 
MED1, a coactivator of TR. Such relationships explain not only the requirement 
for transcriptional regulation by TR, but extend into the model for maintaining 
TR nuclear retention. Therefore, changes in TR mobility dynamics likely 
involves several proteins working cooperatively with each other and TR. Above 
all, this research provides evidence for the role of MED1 in modifying the 
shuttling dynamics of TR. 
 
FUTURE DIRECTIONS 
The basis of our model for a role of MED1 in TR nuclear retention arose 
from its capacity to affect TR gene transactivation. As we have now shown, 
MED1’s regulation of intracellular distribution patterns extends to TRα1, TRβ1 
and v-ErbA. However, MED1 has previously only been connected to altering the 
transcriptional output of the TRα1 isoform (Belakavadi et al., 2008; Pandey et 
al., 2005). Consequently, we aim to conduct a series of luciferase reporter-gene 
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assays to validate changes in gene transactivation of TRα1 in the presence and 
absence of MED1, but also probe TRβ1 and v-ErbA. From here, we will be able 
to compare our results against the previous studies of TRα1 and add to our 
characterization of MED1 affecting each of the variants. Similarly, we found that 
overexpressing, knocking out, and phosphorylating MED1 each had different 
effects. Thus, it is of interest to compare reporter gene transactivation for our 
targeted TR subtypes under all of these conditions. 
Aside from transcriptional output, we are also interested in revealing 
whether MED1 facilitates regulation of TRβ1 and v-ErbA by direct interaction or 
indirect interaction. The more intriguing of these potential interacting partners is 
v-ErbA. v-ErbA contains several mutations within its LBD (Yen et al., 2001). As 
mentioned earlier, TRα1 and other nuclear receptors interact with MED1 directly 
within the AF2 region of the LBD (Fondell, 2013). An abundance of mutations 
within v-ErbA’s LBD introduces a high possibility for failed interaction between 
v-ErbA with MED1. Despite this, future experiments will test for interaction 
between v-ErbA and MED1 using coimmunoprecipitation assays. In addition to 
v-ErbA, it is logical to simultaneously confirm TRβ1’s interaction with MED1. A 
previous study characterized the interaction of TRβ1 with an alternative 
construct of MED1 (Zhu et al., 1997). Although the pseudo-MED1 contains the 
essential RBDs, it lacks several residues which may be altering the native state 
of the protein in undesirable ways. In summary, the narrow degree of uncertainty 
surrounding the interaction can easily be straightened out by running a parallel 
coimmunoprecipitation or pull-down assay with TRβ1. 
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Examining gene transactivation and binding interactions will lend support 
for MED1’s regulation of TR isoforms, but it will also be important to integrate 
new findings with recent elucidation of the exportins involved with TR export. 
The proposal that exportins 4, 5, and/or 7 interact with NES-H12 of TRα1 and 
TRβ1 suggests MED1 may compete with these exportins for TR binding at this 
site. RNA interference was used in prior studies to exert knockdown of various 
exportins to reveal those that influence TR shuttling (Subramanian et al., 2015). 
Using a combination of this exportin-knockdown approach and TRAP220 MEFs 
we have the potential to find differences in TR shuttling caused explicitly from 
competition between MED1 and exportins for binding the NES-H12 residues. 
In combination, we could couple the knock-down(-out) with two 
applications of shuttling assays. The first incorporates heterokaryons to 
examine whether overall TR shuttling is affected under desired conditions, as 
previously described (Bunn et al., 2001; Grespin et al., 2007). In a recent study, 
FRAP on binucleated cells was used to indicate any variance in the dynamics 
of shuttling in live cells, as well (Subramanian et al., 2015). Through these 
assays, we may be able to tease apart MED1’s role as a coactivator for TR’s 
intrinsic gene regulatory properties but also as an inhibitor to prevent exportins 
from interacting with TR helix 12, thereby elucidating a novel mechanism 
through which MED1 sustains TR nuclear retention. In addition, 
coimmunoprecipitation studies could be used to assess competition between 
MED1 and exportins for binding to TR, in wild-type and MED1-null cells. 
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An alternate hypothesis to further implicate MED1 in regulating TR’s nuclear 
localization was initially synthesized from reports of MED1 consistently shuttling 
to nucleoli of cells after being phosphorylated through ERK signaling (Pandey 
et al., 2005). Before determining that a sufficient level of endogenous MED1 
was present in HeLa cells, via western blotting, we incorporated MED1 
overexpression into our nucleocytoplasmic phosphorylation assays. These pilot 
studies detected not only MED1 aggregates forming in the nucleoli of EGF-
stimulated cells, but also largely in the cells incubated in the absence of T3 (data 
not shown, see Fig. 2 MED1-panel “MED1” for similar phenotype). Notably, we 
noticed a similar aggregate-phenotype under the same T3-absent and EGF-
treated conditions with TRα1, as well (see Fig. 12A). Interestingly, another 
protein that displays this phenotype is p53 (Kruger and Scheer, 2010). p53 
sequesters to and forms aggregates of similar frequency as TRα1 and MED1. 
In conjunction, Qi et al. (1997) discovered how p53 interacts with the DBD of 
TRα1 when T3 isn’t bound, providing a possible explanation for the T3-absent 
phenotype we observed. Additionally, other studies have confirmed that p53 
independently interacts with MED1 (Drané et al., 1997; Ito et al., 1999). 
Although all three proteins are paired together in transcriptional regulation and 
compartmental localization does not constitute interaction, these connections 
nonetheless point to the intriguing possibility for a novel regulatory mechanism 
that would ultimately add to the complexity of TR nuclear retention. 
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